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Novelty & Impact Statements 
The identification of specific biomarkers related to CRC risk is essential to understand cancer 
aetiology and mechanisms of progression. This is the first time that evidence of associations 
between a wide range of non-genetic biomarkers and colorectal cancer (CRC) risk from a huge 
number of epidemiological works were evaluated. Three associations detected from meta-analyses 
of observational studies were classified as suggestive, three and seven associations detected from 
Mendelian randomisation studies were classified as causality and non-causal respectively.  
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Abstract 
Several associations between non-genetic biomarkers and colorectal cancer (CRC) risk have 
been detected, but the strength of evidence and the direction of associations are not confirmed. We 
aimed to evaluate the evidence of these associations and integrate results from different 
approaches to assess causal inference. We searched Medline and Embase for meta-analyses of 
observational studies, meta-analyses of randomised clinical trials (RCTs) and Mendelian 
randomisation (MR) studies measuring the associations between non-genetic biomarkers and CRC 
risk and meta-analyses of RCTs on supplementary micronutrients. We repeated the meta-analyses 
using random-effects models and categorised the evidence based on pre-defined criteria. We 
described each MR study and evaluated their credibility. Seventy-two meta-analyses of 
observational studies and 18 MR studies on non-genetic biomarkers and six meta-analyses of RCTs 
on micronutrient intake and CRC risk considering 65, 42 and five unique associations respectively 
were identified. No meta-analyses of RCTs on blood level biomarkers have been found. None of the 
associations were classified as convincing or highly suggestive, three were classified as suggestive 
and 26 were classified as weak. For three biomarkers explored in MR studies, there was evidence of 
causality and seven were classified as likely non-causal. For the first time, results from both 
observational and MR studies were integrated by triangulating the evidence for a wide variety of 
non-genetic biomarkers and CRC risk. At blood level, lower vitamin D, higher homeostatic model 
assessment-insulin resistance and human papillomavirus infection were associated with higher CRC 
risk while increased linoleic acid and oleic acid and decreased arachidonic acid were likely causally 
associated with lower CRC risk. No association was found convincing in both study types. 
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Introduction  
Colorectal cancer (CRC) is the third most common cancer, and the second leading cause of 
cancer death globally.1 More than 1.8 million new cases and 881,000 deaths were estimated to have 
occurred in 2018.1 Furthermore, although there are stable or descending trends in many high-
income countries, their age-specific incidence and mortality rates remain among the highest in the 
world, especially the incidence among young adults.2,3  
A biomarker is defined as a cellular, biochemical, or molecular alteration that can be 
measured and is used to objectively evaluate normal biological or pathological processes.4 Different 
types of biomarkers have been investigated in relation to CRC risk. Environmental factors play an 
important role in the aetiology of CRC through modulating differentiation, apoptosis, angiogenesis, 
proliferation and immune processes against endothelial cells.5 Identifying specific biomarkers related 
to CRC risk is important for understanding cancer aetiology and mechanisms of progression as well 
as early detection and cancer screening that could consequently reduce CRC mortality. The aims of 
this review were: (i) to identify meta-analyses of observational studies, meta-analyses of randomised 
clinical trials (RCTs) and Mendelian randomisation (MR) studies on non-genetic biomarkers and CRC 
risk; (ii) to evaluate the observed associations and classify the level of credibility of the evidence; and 
(iii) to integrate the evidence across different approaches using an evidence triangulation 
framework. Genetic risk factors have been recently explored in a number of field synopses6,7 and 
meta-analyses of genome wide association studies,8,9 and are not considered in this work. 
Methods 
Search strategy and eligibility criteria 
Two reviewers searched Medline and Embase to identify meta-analyses of observational 
studies (01 Jan 2010 to 14 Jun 2019), meta-analyses of RCTs (01 Jan 2010 to 14 Jun 2019) and MR 
studies (up to 20 Jun 2019) investigating the association between non-genetic biomarkers and CRC 
risk. As no meta-analyses of RCTs on biomarkers were identified, we included meta-analyses of RCTs 
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(01 Jan 2010 to 14 Jun 2019) on micronutrient intake as proxies of micronutrient blood levels. 
Systematic reviews without meta-analyses were excluded. Meta-analyses of observational studies 
on non-genetic biomarkers and CRC risk published before 2010 had been previously reviewed in a 
published umbrella review.10 The main results of these studies were extracted from the published 
umbrella review and were further evaluated and assessed together with additional studies published 
from 2010 onwards. A parallel review was conducted by a third reviewer. In the case of any 
discrepancy in assessments, a final decision was made after discussion. The details of all search 
strategies are provided in Supplementary Table 1. We first reviewed the title and abstract of the 
identified studies and then evaluated the full text of all potential eligible studies. We manually 
checked the references of all retrieved articles to include any missed relevant studies. Studies 
investigating the associations between genetic or non-genetic biomarkers and CRC screening, 
diagnosis, survival and prognosis were excluded.  
Data extraction 
One investigator extracted information from each eligible study and two other investigators 
checked the extracted data. A fourth investigator was involved to judge any discrepancies. For meta-
analyses of observational studies, we extracted the first author, year of publication, number of 
studies considered, epidemiological study design, biomarker details, outcome and study population. 
We also recorded the study specific relative risk estimates (risk ratio, odds ratio, hazard ratio, 
standard mean difference, weighted mean difference, standardized correlation coefficient), details 
of the applied statistical models, correspondent confidence intervals and number of cases and 
participants. For meta-analyses of RCTs on micronutrient intake, we further extracted the dose and 
duration of supplementation, number of events and type of intervention in the control group. For 
MR studies, we extracted: the exposure, study design, effect estimate unit, sample size, population 
ethnicity for both exposure and outcome groups, main MR estimate and any sensitivity analyses for 
the associations of genetic instruments with the exposure and outcome, total variance level 
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explained by the genetic instrument assuming an additive model (R2), and the approximate statistical 
power (where presented). 
Statistical analysis 
For the meta-analyses of observational studies, we re-estimated the summary effect size 
and its confidence interval. As the most commonly used DerSimonian and Laird (DL) estimator tends 
to underestimate the 95% CI when less than 10 studies are included,11 we used the Hartung-Knapp-
Sidik-Jonkman (HKSJ) method as the main random effect estimator.12 The HKSJ estimator 
consistently results in more adequate error rates even when the number of studies is small or 
between studies heterogeneity exists.12,13 The meta-analysis P value threshold was set at 0.05. The 
Paule-Mandel (PM) estimator could give an accurate result when between study heterogeneity is 
large but the number of studies is not small.13 Therefore, DL14 and PM15 methods were also applied 
as sensitivity analyses. We quantified the heterogeneity of each meta-analysis by calculating the I2 
value and its 95% prediction interval.16,17 We used the Egger regression asymmetry test to estimate 
any small study effect.18 The excess significance test was performed to evaluate whether the 
observed number of studies with positive results was significantly greater than the expected number 
by using a chi square test.19 For both the small study effect and the excess significance test we used 
P<0.1 as the threshold.                        
Stata version 14.0 and “metafor” package20 in R 3.5.1 were used for statistical analysis. Two-
tailed P values were used.  
Credibility Assessment 
If there were more than one meta-analysis of observational studies or more than one MR 
study investigating the association between the same biomarker and CRC risk, we compared the 
direction, level of statistical significance (P≤0.05) and effect size. The most recent meta-analysis with 
the largest number of prospective studies was retained for further analysis. The most recent MR 
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study (unless a previous MR study employed a stronger genetic instrument and/ or had a larger 
sample size at the outcome arm) was retained for further comparison. 
If we identified meta-analyses of observational studies and MR studies investigating the 
same biomarker, we compared the direction and level of statistical significance (P≤0.05). All 
associations explored in meta-analyses of observational studies and/ or MR studies are presented in 
an evidence triangulation plot.21,22   
We categorised the evidence from meta-analyses of observational studies for each eligible 
biomarker in four categories according to previously defined criteria that considered the quantified 
evidence, statistical significance, heterogeneity, small study effect, excess significance bias and 
prediction interval (convincing or class I, highly suggestive or class II, suggestive or class III, weak or 
class IV and no association).23,24 The evidence classification criteria are described in Table 1. For each 
convincing or highly suggestive association, we re-checked the eligibility for each individual study, 
re-evaluated the accuracy of extracted data and reassessed the evidence after restricting the 
analysis to prospective cohort studies.  
Associations detected from MR studies were categorized into ‘Evidence of causality’, ‘Likely 
non-causal’ and ‘Unknown’ by considering statistical significance (p<0.05), pre-estimated power 
(Power≥0.8 regarded as sufficient) and evidence of bias due to directional pleiotropy (Table 1).   
Results 
The literature search returned 9227 hits for the meta-analyses of observational studies and 
RCTs, and returned 75 hits for MR studies. After applying the pre-defined inclusion and exclusion 
criteria, 72 meta-analyses of observational studies, 18 MR studies and six meta-analyses of RCTs on 
supplementary micronutrients were identified (Figure 1).  
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Meta-analyses of observational studies  
A total of 145 effect estimates for 65 unique biomarkers were extracted from the 72 
included meta-analyses of observational studies (Supplementary Table 4). The median number of 
included component studies for each meta-analysis was 7 (range: 2 – 31). The median number of 
cases was 1,170 (range: 37 – 62,814) and of participants was 4,240 (range: 76 – 7,725,310). More 
than one meta-analysis of observational studies was identified for 20 biomarkers (Supplementary 
Table 6): helicobacter pylori infection (H. pylori, n=9), human papillomavirus infection (HPV, n=8), 
blood levels of folate (n=6), blood levels of vitamin B12 (n=5), blood levels of vitamin B6 (n=5), blood 
levels of vitamin B2 (n=2), blood levels of 25-hydroxyvitamin D (n=10), C-reactive protein (CRP, n=3), 
interleukin-6 (IL-6, n=2), fasting glucose (n=6), C peptide (n=3), IGF-1 (n=3), IGF-2 (n=2), insulin-like 
growth factor-binding protein 3 (IGFBP-3, n=2), triglycerides (n=3), high-density lipoprotein 
cholesterol (HDL-cholesterol, n=2), adiponectin (n=7), leptin (n=4), telomere length (n=3) and 
homocysteine (n=3). Seventeen out of the 20 (85%) overlapping meta-analyses agreed on the 
direction of the effect estimate, 12 of these 17 agreed on the level of statistical significance and 10 
of these 12 associations were statistically significant (Supplementary Table 6). 
After removing the overlapping meta-analyses, a total of 65 unique biomarkers were 
retained for further statistical analysis (Figure 3, and Supplementary Table 2 & 7). We categorized 
the biomarkers into seven categories: fatty acid/lipid metabolism biomarkers (n=14), micronutrients 
(n=10), infectious agents (n=13), inflammatory markers (n=2), insulin related biomarkers (n=10), 
protein/amino acids (n=10) and other biomarkers (n=6).  
A total of 29 associations among the 65 non-overlapping meta-analyses of observational 
studies (45%) were statistically significant (P<0.05) by using the HKSJ meta-analysis estimator 
(Supplementary Table 2, Figure 2). Sensitivity analyses using the DL and PM estimator are presented 
in Supplementary Table 7. Eight and five associations were upgraded when using DL estimator or the 
PM estimator instead of the HKSJ estimator respectively. Sixteen out of the 29 significant biomarkers 
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were associated with increased CRC risk. In these 29 statistically significant associations, 7 (24%) had 
P<0.001, 24 (83%) had a 95% prediction interval that excluded null, 14 (48%) had more than 1,000 
cases, 13 (45%) had no obvious large heterogeneity (I2<50%), 20 (69%) were not subject to small-
study effect or excess significance bias (Supplementary Table 2). After applying the credibility 
criteria, one biomarker (fasting glucose [RR (95% CI): 1.27 (1.11, 1.45)]) was classified as highly 
suggestive and three biomarkers were classified as suggestive (homeostatic model assessment-
insulin resistance [HOMA-IR; RR (95% CI): 1.56(1.22, 1.98)], 25-hydroxyvitamin D [RR (95% CI): 
0.67(0.54, 0.83)] and HPV [RR (95% CI): 3.52(1.77, 7.00)]). For the associations classified as ‘highly 
suggestive’, we checked the eligibility of each component study, evaluated the accuracy of the 
extracted data and reassessed the evidence after restricting the analysis to only including 
prospective studies. The evidence of association between fasting glucose and CRC risk was 
downgraded to ‘weak’.  
We identified six meta-analyses of RCTs on associations between supplementary 
micronutrients and CRC risk, but none of them reported a statistically significant association 
(Supplementary Table 8).  
Mendelian randomisation studies 
Sixty-six MR studies were extracted from 18 publications (Supplementary Table 5). The 
median number of cases for the outcome arm of each included MR study was 13,012 (range: 329-
30,480), the median number of participants was 36,137 (range: 727-382,756) and the median 
variance explained by each genetic instrument was 2.92% (range: 0.3-60.4%). Eight (12%) MR studies 
had enough power (≥0.8) to detect a statistically significant effect estimate. Overlapping MR studies 
were detected for 14 biomarkers (Supplementary Table 6). Nine of the 14 MR studies agreed on the 
direction of the effect size and eight of which agreed on the level of statistical significance: 
overlapping MR studies for plasma arachidonic acid (n=2) and plasma linoleic acid (n=2) agreed on 
the direction of effect size and the effect size estimates were statistically significant; overlapping MR 
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studies for adiponectin (n=3), fetuin-A (n=2), docosapentaenoic acid (DPA, n=2), DHA (n=2), low-
density lipoprotein cholesterol (LDL-cholesterol, n=3) and telomere length (n=2) were concordant in 
the direction but the effect size estimates were not statistically significant; overlapping MR studies 
for total cholesterol (n=2) agreed on the direction but not on the level of statistical significance; MR 
studies for blood levels of 25-hydroxyvitamin D (n=8), EPA (n=2), triglyceride (n=3), HDL-cholesterol 
(n=3) and CRP (n=3) neither agreed on direction nor on statistical significance.  
The biomarkers of the 66 MR analyses were categorized into six categories: micronutrients 
(n=17), fatty acid/lipid metabolism biomarkers (n=30), inflammatory markers (n=4), protein/amino 
acid (n=9), insulin related markers (n=4) and other biomarkers (n=2) (Supplementary Table 5). Nine 
(14%) biomarkers (stearic acid, arachidonic acid [n=2], linoleic acid [n=2], oleic acid, palmitoleic acid, 
total cholesterol and CRP) reported statistically significant associations (at P<0.05 or at a study 
specified threshold due to multiple testing). After removing the overlapping MR studies, 42 
biomarkers were retained for analysis (Supplementary Table 3, Figure 3), three biomarkers 
(arachidonic acid [OR (95% CI): 1.05(1.03, 1.07)], linoleic acid [OR (95% CI): 0.95(0.93, 0.97)] and 
oleic acid [OR (95% CI): 0.77(0.65, 0.92)]) with statistically significant effect estimates and without 
evidence of biological pleiotropy were classified as having ‘Evidence of causality’. Seven MR studies 
were categorised as ‘Likely non-causal’, since these studies had enough statistical power and no 
evidence of biological pleiotropy, but they were statistically non-significant (LDL–cholesterol, omega-
6 polyunsaturated fatty acids, total cholesterol, selenium, vitamin B12, telomere length, 
adiponectin).  
Twenty non-genetic biomarkers were analysed in both meta-analyses of observational 
studies and MR studies (Supplementary Table 6, Figure 2). Ten of the 20 biomarkers (25-
hydroxyvitamin D, selenium, vitamin E, total cholesterol, LDL-cholesterol, CRP, fasting glucose, 
glycated haemoglobin [HbA1C], adiponectin, telomere length) agreed on the direction of the effect 
size, six (selenium, vitamin E, total cholesterol, LDL-cholesterol, HbA1C, telomere length) of which 
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agreed on the level of statistical significance (not significant). One biomarker (25-hydroxyvitamin D) 
was analysed by three different study types (meta-analysis of observational study, MR studies and 
meta-analysis of RCTs on supplementary vitamin D), but only the meta-analyses of observational 
studies reported a statistically significant association.  
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Discussion 
In this study, a comprehensive overview of associations between a wide range of non-
genetic biomarkers and CRC risk was conducted by triangulating evidence from meta-analyses of 
observational studies, MR studies and meta-analyses of RCTs. The non-genetic biomarkers for CRC 
risk which were studied covered 7 categories and CRC risk was associated with 34 examined 
biomarkers. There is a gap of meta-analyses of RCTs or even individual RCTs on biomarkers of CRC 
risk and these were only examined in observational studies. We, therefore, included meta-analyses 
of RCTs of supplementary micronutrients as proxies.  
Meta-analyses of observational studies 
Twenty-nine biomarkers were associated with CRC risk at p<0.05 from meta-analyses of 
observational studies, but none of these association was classified as convincing or highly suggestive. 
Of these 29 statistically significant associations, three (25-hydroxyvitamin D, HPV and HOMA-IR 
[HOMA-IR=glucose × insulin/405]) were classified as suggestive and 26 as weak.  
The association between vitamin D concentration and CRC risk was classified as suggestive 
(Class III) and indicated that a higher blood concentration of vitamin D was associated with a 33% 
decrease in CRC risk. This result was consistent among all eight overlapping meta-analyses. 
Experimental studies based on mouse models have indicated that the potent steroid hormone 
Calcitriol (the active form of vitamin D) may play a protective role against CRC through the regulation 
of proliferation, pro-differentiation, pro-apoptosis, anti-angiogenesis and immune modulation.25 
However, results from RCTs do not support a causal role between supplementary vitamin D (from 
800IU/day to 1000 IU/day with or without calcium supplementation for 1 to 7 years) and CRC risk 
(Supplementary Table 8). Similarly, the eight overlapping MR studies included in this review did not 
identify a causal association between blood level of vitamin D and CRC risk (Supplementary Table 6). 
Therefore, currently, there is no evidence for a clear causal role of vitamin D on CRC risk. It is also 
possible that the non-significant results from RCTs and MR studies are due to the distinct limitations 
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of these two study designs, such as limited follow-up time, insufficient supplementary dose and 
contamination of controls for RCTs and collider bias, limited power and potential pleiotropy for MR 
studies. 
A statistically significant association between diabetes and CRC risk has been previously 
identified by an umbrella review published in 2014.26 In the current study, among the insulin related 
biomarkers, HOMA-IR (a method to quantify insulin resistance based on the blood concentration of 
glucose and insulin) showed suggestive evidence (Class III) for an association with a higher risk of 
CRC. Similarly, IGF-1 and fasting glucose had weak evidence for an association with CRC risk. 
Elevated glucose and insulin levels may increase CRC risk through their pro-proliferation, pro-
angiogenesis and apoptosis inhabitation effects against tumour cell.27 For example, exposure to high 
glucose could lead to increased generation of reactive oxygen intermediates and subsequently could 
induce apoptosis of endothelial cells.28 In addition, hyperglycaemia could increase the concentration 
of circulating inflammatory cytokines leading to chronic inflammation, which has been suggested to 
relate to tumour generation.29,30 However, in this review, we did not find evidence of an association 
between inflammatory markers and CRC risk. The tumour cell growth simulated by high 
concentrations of insulin through the activation of IGF-1, and the possible protective effect of the 
use of metformin (found in a meta-analysis including 12 cohort studies, seven case-controls studies 
and one RCT)31 on CRC development further supports the insulin-CRC association. In conclusion, 
preclinical and epidemiological evidence supports an association between insulin related biomarkers 
on CRC risk, but causality is not supported by MR studies. We should note that diabetes shares many 
risk factors with CRC, which could explain the observed associations from observational studies.  
Interestingly, seven different types of pathogenic micro-organisms were found to be related 
to CRC risk, but most of the evidence was classified as weak due to small number of cases. Only HPV 
showed a suggestive association with CRC risk. HPV is a non-enveloped double stranded DNA virus 
with more than 170 types. Twelve of these types are considered as causal risk factors for cervical 
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cancer (known as high-risk HPV types) by IARC Monographs.32,33 In addition, HPV 16, HPV 18 and HPV 
33 have commonly been found in CRC cases.34,35 The potential mechanisms of HPV on colorectal 
carcinogenesis include viral integration in host cells and expression of E6 and E7 oncoproteins, 
however, evidences of whether HPV infection is truly involved in colorectal carcinogenesis is still not 
convincing.36 Furthermore, this finding should be interpreted with caution, since the HPV-CRC 
association was analysed without stratifying by HPV type. Meanwhile, all the included meta-analyses 
synthesised retrospective observational studies, therefore the observed associations could be due to 
reverse causality. 
Overall, meta-analyses of observational studies indicated weak associations between non-
genetic biomarkers and CRC risk. In this review, only seven out of 65 associations fulfilled the P-value 
threshold of convincing evidence, and of these three were based on evidence from less than 1000 
cases, three did not have a statistically significant p-value for their largest individual study and for 
one there was evidence of small study effect bias and excess significance bias. Despite weak 
evidence after applying the pre-defined credibility criteria, we cannot ignore the clinical importance 
of these associations. Notably, most (85%) of the overlapping studies agreed on the direction of 
effect estimate and over half (60%) agreed on both the direction and statistical significance.  
Mendelian randomisation studies 
Almost half of the biomarkers identified from MR studies were biomarkers of fatty acid / 
lipid metabolism. Most of the detected MR studies had insufficient power (<0.8). There were nine 
MR studies that reported statistically significant results. After retaining the largest MR study for each 
biomarker and applying the pre-defined assessment criteria, we found evidence that high blood 
levels of linoleic acid and oleic acid and low blood levels of arachidonic acid were associated with 
low CRC risk. Conversely, LDL–cholesterol, omega-6 polyunsaturated fatty acids (n-6 PUFAs), total 
cholesterol, selenium, vitamin B12, telomere length and adiponectin were not found to be 
associated with CRC risk.  
16 
 
n-3 and n-6 PUFAs are essential fatty acids and cannot be produced in the human body.37 38 
The beneficial effects of high levels of n-3 PUFAs and low levels of n-6 PUFAs on CRC risk reduction 
remain debatable. In this review, a weak protective effect of n-3 PUFAs on CRC risk was detected 
from meta-analyses of prospective observational studies while MR analyses did not show any 
evidence of causality. Similarly, RCTs did not report any association between supplementation of n-3 
fatty acids (combination of EPA and DHA) and CRC incidence.39,40 Arachidonic acid is an n-6 PUFA, 
which in this review is suggested to causally increase the risk of CRC. The potential mechanism is 
that arachidonic acid can regulate CRC development through the inhibition of cyclooxygenase 
(COX)/lipoxygenase (LOX) and has a competitive relation to DPA in terms of COX enzyme activity.37,41 
Oleic acid and linoleic acid are two of the main components of olive oil and have been examined as 
protective biomarkers for CRC risk by MR studies in this review. These findings, along with evidence 
from a literature review on olive oil intake and a cohort study on Mediterranean diet,42,43 support 
the beneficial effect of oleic acid and linoleic acid on CRC risk. However, the genetic instruments for 
the two n-6 PUFAs are similar, which indicates the possibility that arachidonic acid and linoleic acid 
may share the same pathway to influence CRC risk and represent vertical pleiotropy.    
Overall, we found that there was either lack of evidence or that the credibility of evidence 
varied across the three different study designs. For instance, evidence detected from meta-analyses 
of observational studies was not confirmed by MR studies or meta-analyses of RCTs on 
supplementary micronutrients (i.e. in vitamin D). This may be either due to differences in the study 
designs (observational study tests the presence of associations while MR study and RCT explore 
causality) or due to their inherent distinct limitations and biases. Conversely, four ‘likely non-causal’ 
associations identified from MR studies also were reported as negative results by meta-analyses of 
observational studies, i.e. selenium, total cholesterol, LDL–cholesterol and telomere length.  
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Strengths and limitations 
This umbrella review presents for the first time, integrated evidence from meta-analyses of 
observational studies, MR studies and RCTs with the aim to improve our understanding of the 
associations between non-genetic biomarkers and CRC risk.  Each of the included studies have 
different strength and limitations and, if consistent, could strengthen our confidence in findings.44 
The umbrella review design has a number of strengths as previously summarised.45-48 It also has 
several limitations. First, in an umbrella review, only systematic reviews with meta-analyses and MR 
studies are included, thus associations with biomarkers that have not been included in meta-
analyses are not evaluated (i.e. circulation sex hormone levels).49,50 We did not search for pre-print 
articles which are not peer reviewed, and we have therefore not included studies of newly detected 
CRC related biomarkers. Given that no meta-analyses of RCTs on biomarkers were identified, we 
included meta-analyses of RCTs on intake of micronutrients as proxies of micronutrient levels 
measured in blood. Along with the inclusion of MR studies, these might offset the absence of meta-
analyses of RCTs. A note of caution though is the uncertain association between supplementary dose 
and physiological dose of micronutrients across participants. Second, there might have been 
heterogeneity of effects based on anatomical site,51 gender, body mass index, diabetes mellitus and 
other risk factors,52 but we did not perform any subgroup analysis. Third, we did not evaluate the 
quality assessment of the component studies of each meta-analysis of observational studies (apart 
from meta-analyses classified as convincing or highly suggestive) and the eligibility of component 
studies depended on the authors of each meta-analysis. Most of the included meta-analyses 
estimated the quality of the individual studies by applying the Newcastle-Ottawa Scale, which has 
low reliability between independent reviewers.53 Fourth, the limitations of the adopted credibility 
assessment criteria have been described previously and also apply here.45-48 Finally, evidence from 
meta-analyses of observational studies could be biased by confounding factors or by reverse 
causality. 
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Conclusion  
This umbrella review represents a comprehensive summary and evidence triangulation of a 
wide range of CRC risk associated non-genetic biomarkers. In conclusion, we report and classify the 
evidence for non-genetic biomarkers detected from meta-analyses of observational studies, MR 
studies and meta-analyses of RCTs. Convincing evidence of a clear role of a non-genetic biomarker in 
CRC risk has not been detected from meta-analyses of observational studies. From MR studies, a 
likely causal increased CRC risk with arachidonic acid and a likely causal decreased risk with linoleic 
acid and oleic acid were suggested. Conversely, seven biomarkers (LDL–cholesterol, n-6 PUFAs, total 
cholesterol, selenium, vitamin B12, telomere length and adiponectin) are likely non-causal. Four 
(LDL–cholesterol, total cholesterol, selenium and telomere length) of these seven biomarkers have 
consistent results (likely non-causal) from MR and meta-analyses of observational studies. 
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Tables 
Table 1 Credibility Assessment Criteria for Meta-analyses of Observational Studies and Mendelian 
randomisation study 
Evidence category  Criteria 
Meta-analyses of observational studies 
    Convincing (class I) P < 0.001; >1000 cases; P < 0.05 in the largest study.  
A 95% PI that excluded the null; I2 <50%. 
No evidence of small-study effect (P > 0.10); and no excess significance 
bias (P > 0.10). 
    Highly suggestive (class II) P < 0.001; >1000 cases.  
P < 0.05 in the largest study; 
    Suggestive (class III) P < 0.001; >1000 cases  
    Weak (class IV) P < 0.05 
    No association P ≥ 0.05 
Mendelian randomisation study 
    Evidence of causality P<0.05 or threshold set up by individual study due to multiple testing; 
evaluated pleiotropy but have no evidence of directional pleiotropy. 
    Likely non-causal P>0.05 or threshold set up by individual study due to multiple testing; 
Power≥0.8; Consistent evidence between main MR analysis and 
sensitivity analyses; Evaluated pleiotropy but have no evidence of 
directional pleiotropy. 
    Unknown Studies that cannot be classified as either ‘Evidence of causality’ or 
‘Likely non-causal’. 
PI: prediction interval 
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Figure legends 
Figure 1A: PRISMA flow diagram illustrating the study screening and selection process for meta-
analyses of observational studies and meta-analyses of randomised clinical trials (performed on 
14/06/2019) 
Figure 1B: PRISMA flow diagram illustrating the study screening and selection process for 
Mendelian randomisation studies (performed on 20/06/2019) 
Figure 2 Evidence triangulation bubble plot for biomarkers detected from meta-analyses of 
observational studies and MR studies 
The bubble size of meta-analyses of observational studies represents the number of cases and the bubble size of MR studies represents 
the number of CRC cases divided by 5. MR only: Biomarkers only detected in MR studies, MA only: Biomarkers only detected in meta-
analyses of observational studies, LA: Linoleic acid, AA: Arachidonic acid, V-B12/B6/D/E/A: Vitamin B12/B6/D/E/A, Adiponectin1: 
Adiponectin in European and United State population, Adiponectin2: Adiponectin in European population only, TC: Total cholesterol, LDL: 
Low-density lipoprotein cholesterol, HDL: High-density lipoprotein cholesterol, TL: Telomere length, n-6 PUFA: n-6 polyunsaturated fatty 
acid,  IGF-1/2: Insulin-like growth factor 1/2, EPA: Eicosapentaenoic acid, DHA: Docosahexaenoic acid, DPA: Docosapentaenoic acid, CRP: 
C-reactive protein,  IL-6: Interleukin 6, HbA1C: glycated hemoglobin,  GDF-15: Growth differentiation factor 15, IGE: Serum 
immunoglobulin E, ALA: α-Linolenic acid, DGLA: Dihomo-γ-linolenic acid, MUFA: Mono-unsaturated fatty acids, Blood-A/B/AB/O: Blood 
group A/B/AB/O, F-glucose: Fasting glucose, F-insulin: Fasting insulin, HPV: Human papillomavirus, n-3 PUFA: long chain n-3 
polyunsaturated fatty acid, HOMA-IR: homeostatic model assessment-insulin resistance, MMP7: Matrix metalloproteinase-7, S-bovis: 
Streptococcus bovis, IGFBP 1/2/3: Insulin-like growth factor-binding protein 1/2/3, CD26: Dipeptidyl peptidase IV, S-bovis-faeces: 
Streptococcus bovis in faeces, H.pylori: Helicobacter pylori, B.b: Bifidobacterium, E.b: Enterobacteriaceae, HCI: Human cytomegalovirus 
infection, F.n: F. nucleatum, Hcy: Homocysteine, TB: Total bacteria, F.b: Faecalibacterium prausnitzii, E.c: Escherichia coli, L.b: 
Lactobacillus, F-proinsulin: fasting proinsulin 
Figure 3A Forest plot for evidence of associations between non-genetic biomarkers and CRC risk 
from meta-analyses of observational studies (metric: odds ratio and risk ratio) 
Figure 3B Forest plot for evidence of associations between non-genetic biomarkers and CRC risk 
from meta-analyses of observational studies (metric: standardized mean difference) 
Figure 3C Forest plot for evidence of associations between non-genetic biomarkers and CRC risk 
from MR studies (metric: odds ratio) 
CRC: colorectal cancer, CI: confidence interval, results of meta-analyses were analysed by using  Hartung-Knapp-Sidik-Jonkman method, 
RR: risk ratio, SMD: standard mean difference, OR: odds ratio, LC n-3 PUFA: long chain n-3 polyunsaturated fatty acid, EPA: 
Eicosapentaenoic acid, DHA: Docosahexaenoic acid, DPA: Docosapentaenoic acid, HDL: high-density lipoprotein cholesterol, LDL: low-
density lipoprotein cholesterol, HPV: Human papillomavirus, H.pylori: Helicobacter pylori, CRP: C-reactive protein, IL-6: Interleukin 6, 
HOMA-IR: homeostatic model assessment-insulin resistance, IGF 1/2: Insulin-like growth factor 1/2, IGFBP 1/2/3: Insulin-like growth 
factor-binding protein 1/2/3, HbA1c: glycated hemoglobin, MMP7: matrix metalloproteinase-7, CD26: dipeptidyl peptidase IV, *: total 
number of participants for exposure and CRC Genome-wide association studies, SNP: Single Nucleotide Polymorphism, GRS: genetic risk 
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score, AA: arachidonic acid, DGLA: dihomo-γ-linolenic acid, LA: linoleic acid, ALA: α-Linolenic acid, GDF-15: Growth differentiation factor 
15. 
  Supplementary tables 
Supplementary Table 1 Search strategy  
Search strategy for meta-analyses of observational studies and randomised clinical trials 
 MEDLINE   EMBASE 
1 
((rectal or rectum or colonic or colon or 
colorectal or bowel* or sigmoid or intestin*) adj3 
(cancer* or carcinoma* or neoplas* or tumor* or 
tumour* or adenocarcinoma* or 
adeno?carcinoma* or adenom* or lesion* or CRC 
)).mp. 
1 
((rectal or rectum or colonic or colon or 
colorectal or bowel* or sigmoid or intestin*) 
adj3 (cancer* or carcinoma* or neoplas* or 
tumor* or tumour* or adenocarcinoma* or 
adeno?carcinoma* or adenom* or lesion* or 
CRC )).mp. 
2  exp Colorectal Neoplasms/ 2 exp colon tumor/ 
3 1 or 2 3 exp rectum tumor/ 
4 meta analy$.tw. 4 exp colon carcinoma/ 
5 metaanaly$.tw. 5 exp colorectal carcinoma/ 
6 (systematic adj (review$1 or overview$1)).tw. 6 exp rectum carcinoma/ 
7 Meta-Analysis/ 7 exp colon cancer/ 
8 exp "REVIEW LITERATURE AS TOPIC"/ 8 exp rectum cancer/ 
9 exp Meta-Analysis as Topic/ 9 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 
10 4 or 5 or 6 or 7 or 8 or 9 10 (meta adj analy$).tw. 
11 3 and 10 11 metaanalys$.tw. 
12  limit 11 to yr="2010 - 2019" 12 
(systematic adj (review$1 or 
overview$1)).tw. 
  13 meta analysis/ 
  14 exp "systematic review"/ 
  15 exp "meta analysis (topic)"/ 
  16 10 or 11 or 12 or 13 or 14 or 15 
  17 9 and 16 
  18 limit 17 to yr="2010 - 2019" 
Search strategy for Mendelian randomisation studies 
((rectal or rectum or colonic or colon or colorectal or bowel* or sigmoid or intestin*) and (cancer or 
carcinoma* or neoplas* or tumor or tumour or adenocarcinoma* or adeno?carcinoma* or adenom* or 
lesion* or CRC) and (Mendelian and randomi*)).mp. 
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Supplementary Table 2 Characteristics and main findings of meta-analyses of observational studies reporting unique non-genetic biomarkers and CRC 
risk (HKSJ estimator) 
First author, Year 
(Citation) Biomarker Comparison 
No of 
studies 
No of 
cases Total No Metric Effect size (95% CI) P value I
2 1PEgger 
95% Prediction 
interval 
2Psig Evidence 
Fatty acid/Lipid metabolism biomarkers 
Yang B,2014 LC n-3 PUFA Highest vs. lowest categories 3 421 1,826 RR 0.58(0.40, 0.84) 0.0042 0.21% 0.78 0.578(0.398, 0.841) NA Weak 
Yang B,2014 Biospecimen EPA 20:5 (n-3) Highest vs lowest categories 4 421 1,826 RR 0.64(0.42, 0.96) 0.0314 9.24% 0.50 0.637(0.422, 0.961) NA Weak 
Yang B,2014 Biospecimen DHA 22:6 (n-3) 
Highest vs. 
lowest categories 4 421 1,826 RR 0.51(0.28, 0.93) 0.0266 46.59% 0.19 0.513(0.284, 0.925) NA Weak 
Yang B,2014 Biospecimen DPA 22:5 (n-3) Highest vs. lowest categories 3 243 1,366 RR 0.56(0.29, 1.07) 0.0788 37.89% 0.46 0.561(0.295, 1.069) NA No 
Yang B,2014 Blood EPA 20:5 (n-3) Mean (% total fatty acids) 5 195 384 SMD -0.98(-2.87, 0.91) 0.308 98.87% 0.01 -0.983(-2.873, 0.907) NA No 
Yang B,2014 Blood DHA 22:6 (n-3) Mean (% total fatty acids) 5 195 384 SMD -0.07(-0.31, 0.17) 0.5718 35.10% 0.41 -0.068(-0.306, 0.169) NA No 
Yang B,2014 Blood DPA 22:5 (n-3) Mean (% total fatty acids) 5 195 384 SMD 0.43(-0.27, 1.12) 0.2292 92.11% 0.00 0.427(-0.269, 1.122) NA No 
Yang B,2014 Adipose EPA 20:5 (n-3) Mean (% total fatty acids) 2 93 204 SMD 0.07(-0.21, 0.36) 0.6083 3.39% / 0.074(-0.208, 0.356) 0.75 No 
Yang B,2014 Adipose DHA 22:6 (n-3) Mean (% total fatty acids) 2 93 204 SMD -0.02(-0.37, 0.32) 0.8999 35.64% / -0.022(-0.368, 0.324) NA No 
Yang B,2014 Adipose DPA 22:5 (n-3) Mean (% total fatty acids) 2 93 204 SMD 0.12(-0.16, 0.39) 0.4082 0.07% / 0.117(-0.160, 0.395) 0.69 No 
Yao X, 2015 HDL-cholesterol Highest vs. lowest categories 12 2,542 136,698 RR 0.83(0.67, 1.04) 0.1043 53.08% 0.39 0.83(0.67, 1.04) 0.01 No 
Yao X, 2015 LDL-cholesterol Highest vs. lowest categories 5 1,626 9,175 RR 1.04 (0.57, 1.92) 0.8908 85.67% 0.16 1.04(0.57, 1.92) 0.0002 No 
Yao X, 2015 Total cholesterol Highest vs. lowest categories 28 10,892 7,725,310 RR 1.11(0.98, 1.27) 0.1043 76.10% 0.60 1.12(0.98, 1.27) NA No 
Yao X, 2015 Triglyceride Highest vs. lowest categories 19 8,127 2,252,217 RR 1.17 (0.99, 1.37) 0.0598 47.77% 0.22 1.17(0.99, 1.37) NA No 
Infectious agents 
Ibragimova 
MK,201825 HPV 
CRC tissue vs 
Cancer-free 
tissue 
17 1,722 2,468 RR 3.52(1.77, 7.00) 0.0003 75.66% 0.6453 3.52(1.77, 7.00) NA Suggestive 
Bai B,2016 Human cytomegalovirus infection 
Tumour tissue vs 
normal tissue 4 480 960 OR 6.47(4.23, 9.89) 6.7839E-18 13.74% 0.70 6.47(4.23, 9.89) 0.99 Weak 
Boleij A,2011 Streptococcus bovis CRC in S.bovis type 1 & type 2 6 189 340 OR 9.44(4.43, 20.11) 5.95E-09 18.72% 0.57 9.44(4.43, 20.11) NA Weak 
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Liu C,2016 H.pylori CRC vs non-CRC 20 3,228 4,377 OR 1.38(1.01, 1.89) 4.00E-02 82.00% 0.90 1.38(1.02, 1.89) 0.27 Weak 
Repass J,2018 F. nucleatum 
CRC tissue vs 
adjacent normal 
tissue 
2 139 278 r 0.40(0.16, 0.63) 0.00100 40.05% / 0.38(0.16, 0.56) NA Weak 
Liu H,2016 Enterobacteriaceae 
Healthy controls 
(logarithmic 
number of 
bacteria per 
gram stool) 
2 37 76 SMD 2.62(0.62, 4.61) 0.0101 87.87% / 2.62(0.62, 4.61) NA Weak 
Liu H,2016 Bifidobacterium 
Healthy controls 
(logarithmic 
number of 
bacteria per 
gram stool) 
4 127 315 SMD -3.24(-6.32, -0.16) 0.039 98.08% 0.07 -3.24(-6.32, -0.16) 0.00 Weak 
Liu H,2016 Faecalibacterium prausnitzii 
Healthy controls 
(logarithmic 
number of 
bacteria per 
gram stool) 
3 86 233 SMD -0.31(-0.69, 0.06) 0.1 25.76% 0.60 -0.31(-0.69, 0.06) 0.80 No 
Liu H,2016 Total bacteria 
Healthy controls 
(logarithmic 
number of 
bacteria per 
gram stool) 
3 86 233 SMD 0.29(-0.74, 1.31) 0.5825 87.31% 0.07 0.29(-0.74, 1.31) 0.28 No 
Krishnan S,2014 Streptococcus bovis in faeces CRC vs non-CRC 3 148 414 OR 3.10(0.68, 14.20) 0.1456 56.37% 0.23 3.10(0.68, 14.20) NA No 
Liu H,2016 Lactobacillus 
Healthy controls 
(logarithmic 
number of 
bacteria per 
gram stool) 
4 127 315 SMD -1.85(-5.33, 1.64) 0.2993 99.15% 0.19 -1.85(-5.33, 1.64) 0.00 No 
Liu H,2016 Bacteroides-Prevotella group 
Healthy controls 
(logarithmic 
number of 
bacteria per 
gram stool) 
3 97 255 SMD -0.70(-2.33, 0.94) 0.403 95.30% 0.83 -0.70(-2.33, 0.94) NA No 
Liu H,2016 Escherichia coli 
Healthy controls 
(logarithmic 
number of 
bacteria per 
gram stool) 
2 90 239 SMD 1.38(-1.34, 4.10) 0.3195 97.96% / 1.38(-1.34, 4.10) 0.00 No 
Inflammatory Markers 
Zhou B,2014 CRP 1-unit change in ln (mg/l) 18 4,779 152,942 RR 1.14(1.04, 1.25) 0.0059 72.80% 0.05 1.14(1.04, 1.25) 0.03 Weak 
Zhou B,2014 IL-6 1-unit change in ln (mg/l) 6 1,125 9,909 RR 1.09(0.85, 1.39) 0.4959 47.99% 0.19 1.09(0.85, 1.39) 0.595 No 
Insulin related biomarkers 
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Xu J,2016 Fasting glucose 
Highest vs lowest 
categories 
(mmol/L) 
26 20,390 5,105,567 RR 1.27(1.11, 1.45) 0.0006 66.17% 0.0106 1.27(1.11, 1.45) NA Highly suggestive 
Xu J,2016 HOMA-IR 
Highest vs lowest 
categories 
(fasting glucose 
(mmol/L) × 
fasting insulin 
(mIU/L) / 22.5) 
9 2,956 18,358 RR 1.56(1.22, 1.98) 0.0003 38.91% 0.18 1.56(1.22, 1.99) NA Suggestive 
Xu J,2016 Fasting insulin 
Highest vs lowest 
categories 
(mIU/L) 
11 3,191 26,301 OR 1.40 (1.12, 1.74) 0.0031 24.65% 0.86 1.40(1.12, 1.74) NA Weak 
Chi F,2013 IGF 1 Highest with lowest categories 17 3,807 11,613 OR 1.31(1.05, 1.63) 0.0187 48.42% 0.28 1.31(1.05, 1.63) NA Weak 
Chi F,2013 IGF 2 Highest with lowest categories 6 783 4,007 OR 1.52(0.99, 2.34) 0.0549 42.30% 0.62 1.52 (0.99, 2.34) NA No 
Chi F,2013 IGFBP 1 Highest with lowest categories 7 2,154 6,439 OR 0.81(0.61, 1.09) 0.1585 43.13% 0.42 0.81(0.61, 1.09) 0.2816 No 
Chi F,2013 IGFBP 2 Highest with lowest categories 3 1,348 2,962 OR 0.76(0.41, 1.43) 0.4016 68.77% 0.02 0.77(0.41, 1.43) NA No 
Chi F,2013 IGFBP 3 Highest with lowest categories 16 3,755 11,509 OR 0.88 (0.70, 1.10) 0.268 45.74% 0.31 0.88(0.71, 1.10) 0.5968 No 
Xu J,2016 HbA1c Highest vs lowest categories (%) 8 2,137 45,569 RR 1.25(0.93, 1.67) 0.1414 53.83% 0.30 1.25(0.99, 1.67) NA No 
Xu J,2016 C-peptide Highest vs lowest categories(ng/ml) 11 3,211 13,888 RR 1.35(0.97, 1.89) 0.0788 70.63% 0.73 1.35(0.97, 1.89) 0.776 No 
Micronutrients 
Ma YL,2011 25-hydroxyvitamin D Highest with lowest categories 10 3,142 7,840 RR 0.67(0.54, 0.83) 0.0002 20.49% 0.79 0.670 (0.541, 0.830) NA Suggestive 
Ben S,2018 Vitamin B2 Highest with lowest categories 2 1,593 32,962 RR 0.74(0.57, 0.95) 0.02 9.32% / 0.74(0.58, 0.95) NA Weak 
Larsson SC, 2010 Vitamin B6 
Highest vs lowest 
categories 
(pmol/) 
4 883 2,207 RR 0.53(0.38, 0.71) 0.0012 0.89% 0.97 0.52(0.38, 0.72) NA Weak 
Shiao SPK,2018 Vitamin B12 Mean (pmol/L) 8 3,296 8,290 SMD -0.07(-0.14, -0.004) 0.0384 54.91% 0.03 -0.07(-0.19, 0.05) 0.47 Weak 
Zhang D, 2015 Folate CRC vs healthy controls 12 1,159 2,982 SMD -1.29(-2.29, -0.30) 0.0105 99.57% 0.0442 -1.29(-3.09, 0.51) NA Weak 
Dong YH,2017 Vitamin E Mean (µmol/L) 9 310 5,927 SMD -0.79(-1.63, 0.05) 0.065 96.61% 0.01 -0.79(-1.63, 0.05) 0.3192 No 
Lee JE,2011 1,25-dihydroxyvitamin D Highest with lowest categories 4 625 1,801 OR 1.01(0.66, 1.59) 0.9302 42.59% 0.64 1.020 (0.656, 1.585) NA No 
Vinceti M,2018 Selenium Highest vs. lowest category 8 2,627 712,746 OR 0.86(0.62, 1.18) 0.3509 42.92% 0.7895 0.859(0.624, 1.182) NA No 
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Gumulec J,2014 Serum Zinc  
Largest variation 
among serum 
levels 
5 313 529 SMD 0.05(-3.47, 3.56) 0.9788 99.40% 0.7342 0.05(-3.47, 3.56) 0.00 No 
Gumulec J,2014 Tissue Zinc 
Largest variation 
among tissue 
levels 
10 234 398 SMD -0.76(-3.08, 1.55) 0.5187 98.75% 0.00 -0.76(-3.08, 1.55) 0.1503 No 
Other Biomarkers 
Zhang BL,2015 Blood group A A vs non-A 8 6,931 3,214,941 OR 1.01(0.90, 1.14) 0.8533 75.87% 0.12 1.01(0.90, 1.14) 0.09 No 
Zhang BL,2015 Blood group AB AB vs non-AB 8 6,931 3,191,289 OR 0.94(0.73, 1.21) 0.6416 61.18% 0.44 0.94(0.73, 1.21) NA No 
Zhang BL,2015 Blood group B B vs non-B 8 6,931 3,193,532 OR 1.00(0.91, 1.10) 0.9963 18.12% 0.41 1.00(0.91, 1.10) NA No 
Zhang BL,2015 Blood group O O vs non-O 8 6,931 3,219,151 OR 0.91(0.84, 1.00) 0.0445 54.58% 0.23 0.91(0.84, 1.00) NA Weak 
Naing C,2017 Telomere Length Shortest Q4 vs longest Q2 8 951 2,569 OR 1.02(0.75, 1.40) 0.8842 42.82% 0.34 1.02(0.75, 1.40) NA No 
Jiang R,2016 Enterolactone Per doubling (nmol/l) 3 762 2,408 RR 1.14(0.89, 1.47) 0.2924 66.71% 0.06 1.14(0.89, 1.47) NA No 
Protein & amino acids 
Lu S,2017 Total Adiponectin Highest vs lowest categories 8 3,420 8,937 RR 0.78(0.65, 0.95) 0.0143 39.81% 0.38 0.79(0.65, 0.95) 0.578 Weak 
Yang G,2016 Resistin Mean (ng/mL) 11 965 2,290 SMD 0.65(0.19, 1.11) 0.0059 94.79% 0.94 0.65(0.19, 1.11) NA Weak 
Shiao SPK,2018 Homocysteine Mean (mmol/L) 8 4,047 9,604 SMD 0.13(0.04, 0.21) 0.003 68.35% 0.69 0.13(-0.03, 0.28) NA Weak 
Yu DD,2018 Angiogenin Mean (ng/ml) 2 188 240 SMD 1.53(0.52, 2.54) 0.003 87.41% / 1.53(0.52, 2.54) NA Weak 
Xing XJ,2014 MMP7 Mean (% total fatty acids) 10 625 1,020 SMD 2.31(0.91, 3.71) 0.0013 98.80% 0.00 2.31(-0.24, 4.86) 0.4128 Weak 
Li XX,2014 TLR-4 protein CRC vs healthy controls 3 168 283 OR 4.75(1.16, 19.45) 0.0304 77.55% 0.01 4.75(1.16, 19.46) 0.0181 Weak 
Sun SJ,2016 HER-2 expression CRC vs healthy controls 13 932 1,453 OR 11.82(5.36, 26.08) 9.33E-10 63.02% 0.00 11.82(5.36, 26.08) 0.103 Weak 
Feng Z,2015 Ferritin Mean (ng/ml) 7 277 927 SMD -1.57(-3.06, -0.08) 0.0388 98.50% 0.00 -1.57(-3.06, -0.08) NA Weak 
Ouyang Z,2017 CD26 Tumour cell vs normal cell 9 952 1,809 SMD -0.33(-4.35, 3.70) 0.8737 99.84% 0.45 -0.33(-7.62, 6.97) 0.0098 No 
Gialamas SP,2013 Leptin Mean 23 3,508 7,478 SMD 0.20(-0.32, 0.72) 0.4551 99.03% 0.58 0.20(-0.75, 1.14) 0.000000 No 
CRC: colorectal cancer, CI: confidence interval, HKSJ: Hartung-Knapp-Sidik-Jonkman, 1PEgger: The P value for small study effect test, 2Psig: The P value for excess significance test, RR: risk ratio, SMD: standard mean difference, OR: odds ratio, 
r: standardized correlation coefficient, LC n-3 PUFA: long chain n-3 polyunsaturated fatty acid, EPA: Eicosapentaenoic acid, DHA: Docosahexaenoic acid, DPA: Docosapentaenoic acid, HDL: high-density lipoprotein cholesterol, LDL: low-density 
lipoprotein cholesterol, HPV: Human papillomavirus, H.pylori: Helicobacter pylori, CRP: C-reactive protein, IL-6: Interleukin 6, HOMA-IR: homeostatic model assessment-insulin resistance, IGF 1/2: Insulin-like growth factor 1/2, IGFBP 1/2/3: 
Insulin-like growth factor-binding protein 1/2/3, HbA1c: glycated hemoglobin, MMP7: matrix metalloproteinase-7, CD26: dipeptidyl peptidase IV. 
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Supplementary Table 3 Characteristics and main findings of 42 non-overlapped Mendelian randomisation analyses 
First author, Year 
(Citation) 
Biomarker (Unit) 
 
Power to 
detect given 
effect 
estimates 
Exposure Outcome 
Study 
design 
Main method Main estimate P value Sensitivity analyses 
Consistent 
evidence of 
a causal 
effect 
Evidence 
Sample size Population 
Variance 
(R2) 
explained 
by GI (%) 
Sample size Metric Population 
Micronutrients 
Cornish AJ, 2019 Blood selenium 
1.000|OR≤0.75 
or OR≥1.33 
2,603 
participants 
Queensland 2 
26,397 cases 
and 41,481 
controls 
OR per 
SD 
European 
Two-
sampl
e 
Wald ratio 
0.85 (0.75, 
0.96) 
0.008** 
Weighted median, mode-based estimates, MR-
Egger, leave-one-out analysis 
No Likely non-causal 
Cornish AJ, 2019 Blood zinc 
1.000|OR≤0.75 
or OR≥1.33 
2,603 
participants 
Queensland 4.6 
26,397 cases 
and 41,481 
controls 
OR per 
SD 
European 
Two-
sampl
e 
Maximum 
likelihood 
0.94 (0.86, 
1.03) 
0.179** 
Weighted median, mode-based estimates, MR-
Egger, leave-one-out analysis 
No Unknown 
Cornish AJ, 2019 
Circulating 25-
hydroxyvitamin D 
1.000|OR≤0.75 
or OR≥1.33 
79,366 
participants 
European 2.6 
26,397 cases 
and 41,481 
controls 
OR per 
SD 
European 
Two-
sampl
e 
Maximum 
likelihood 
0.99 (0.90, 
1.09) 
0.895** 
Weighted median, mode-based estimates, MR-
Egger, leave-one-out analysis 
No Unknown 
Cornish AJ, 2019 
Circulating 
carotenoids 
1.000|OR≤0.75 
or OR≥1.33 
1,190 
participants 
Italian 2.8 
26,397 cases 
and 41,481 
controls 
OR per 
SD 
European 
Two-
sampl
e 
Wald ratio 
1.04 (0.94, 
1.15) 
0.451** 
Weighted median, mode-based estimates, MR-
Egger, leave-one-out analysis 
No Unknown 
Cornish AJ, 2019 Iron status 
0.981|OR≤0.75 
or OR≥1.33 
48,972 
participants 
European 1.2 
26,397 cases 
and 41,481 
controls 
OR per 
SD 
European 
Two-
sampl
e 
Maximum 
likelihood 
1.17 (1.00, 
1.36) 
0.049** 
Weighted median, mode-based estimates, MR-
Egger, leave-one-out analysis 
No Unknown 
Cornish AJ, 2019 Serum calcium 
1.000|OR≤0.75 
or OR≥1.33 
39,400 
participants 
European 2.6 
26,397 cases 
and 41,481 
controls 
OR per 
SD 
European 
Two-
sampl
e 
Maximum 
likelihood 
0.93 (0.83, 
1.05) 
0.264** 
Weighted median, mode-based estimates, MR-
Egger, leave-one-out analysis 
No Unknown 
Cornish AJ, 2019 
Serum vitamin A 
(retinol) 
0.879|OR≤0.75 
or OR≥1.33 
5,006 
participants 
Finland, US 0.7 
26,397 cases 
and 41,481 
controls 
OR per 
SD 
European 
Two-
sampl
e 
Maximum 
likelihood 
1.07 (0.78, 
1.47) 
0.663** 
Weighted median, mode-based estimates, MR-
Egger, leave-one-out analysis 
No Unknown 
Cornish AJ, 2019 
Serum vitamin 
B12 
1.000|OR≤0.75 
or OR≥1.33 
45,576 & 
37,341 
participants 
Iceland, 
Denmark 
4.7 
26,397 cases 
and 41,481 
controls 
OR per 
SD 
European 
Two-
sampl
e 
Maximum 
likelihood 
1.21 (1.04, 
1.42) 
0.016** 
Weighted median, mode-based estimates, MR-
Egger, leave-one-out analysis 
No Likely non-causal 
Cornish AJ, 2019 Serum vitamin B6 
0.994|OR≤0.75 
or OR≥1.33 
2,930 
participants 
 1.4 
26,397 cases 
and 41,481 
controls 
OR per 
SD 
European 
Two-
sampl
e 
Wald ratio 
1.04 (0.90, 
1.20) 
0.592** 
Weighted median, mode-based estimates, MR-
Egger, leave-one-out analysis 
No Unknown 
Cornish AJ, 2019 Serum vitamin E 
0.857|OR≤0.75 
or OR≥1.33 
5,006 
participants 
European 0.7 
26,397 cases 
and 41,481 
controls 
OR per 
SD 
European 
Two-
sampl
e 
Maximum 
likelihood 
0.94 (0.76, 
1.17) 
0.600** 
Weighted median, mode-based estimates, MR-
Egger, leave-one-out analysis 
No Unknown 
Fatty acid/Lipid metabolism biomarkers 
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May-Wilson S, 
2017 
Plasma Arachidic 
acid (20:0) (GRS) 
Limited power 
(not specified) 
38,000 parti
cipants 
European / 
9,254 cases 
and 18,386 
controls 
OR per 
SD 
European 
Two-
sampl
e 
Meta-analysis of 
statistics for each 
specific fatty acid 
generated for 
each CRC cohort 
was combined 
under fixed-
effects models 
0.92(0.61, 
1.39) 
0.700 
Where more than one instrument variant was 
available: heterogeneity assessment, random-
effects inverse-variance weighted MR; assessing 
impact of pleiotropy by using IVW and MR-Egger 
methods 
No Unknown 
May-Wilson S, 
2017 
Plasma Palmitic 
acid (16:0) (GRS) 
Limited power 
(not specified) 
38,000 parti
cipants 
European 0.21-0.98 
9,254 cases 
and 18,386 
controls 
OR per 
SD 
European 
Two-
sampl
e 
Meta-analysis of 
statistics for each 
specific fatty acid 
generated for 
each CRC cohort 
was combined 
under fixed-
effects models 
0.97(0.78, 
1.21) 
0.820 
Where more than one instrument variant was 
available: heterogeneity assessment, random-
effects inverse-variance weighted MR; assessing 
impact of pleiotropy by using IVW and MR-Egger 
methods 
No Unknown 
May-Wilson S, 
2017 
Plasma Stearic 
acid (18:0) (GRS) 
Limited power 
(not specified) 
38,000 parti
cipants 
European 
0.01-1.39 
per SNP 
9,254 cases 
and 18,386 
controls 
OR per 
SD 
European 
Two-
sampl
e 
Meta-analysis of 
statistics for each 
specific fatty acid 
generated for 
each CRC cohort 
was combined 
under fixed-
effects models 
1.16(1.01, 
1.35) 
0.040 
Where more than one instrument variant was 
available: heterogeneity assessment, random-
effects inverse-variance weighted MR; assessing 
impact of pleiotropy by using IVW and MR-Egger 
methods 
No Unknown 
Liyanage UE, 
2019 
Plasma DHA 
22:6n-3 
/ 
8,866 partici
pants 
European 0.65 
4,545 cases 
and 270,342 
controls 
combined 
9,254 cases 
and 18,386 
controls 
OR per 
SD 
European 
Two-
sampl
e 
Wald-type ratio 
estimator 
(combining 
estimate with 
those from May-
Wilson et al 2017) 
1.07(0.84, 
1.36) 
0.583* 
IVW estimate without combining with data from 
other study (May-Wilson et al 2017) 
No Unknown 
Liyanage UE, 
2019 
Plasma EPA 
20:5n-3 
/ 
8,866 partici
pants 
European 2.05 
4,545 cases 
and 270,342 
controls 
combined 
9,254 cases 
and 18,386 
controls 
OR per 
SD 
European 
Two-
sampl
e 
IVW (combining 
estimate with 
those from May-
Wilson et al 2017) 
1.06(0.91, 
1.22) 
0.455* 
IVW estimate without combining with data from 
other study (May-Wilson et al 2017) 
No Unknown 
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Liyanage UE, 
2019 
Plasma DPA 
20:5n-3 
/ 
8,866 partici
pants 
European 11.12 
4,545 cases 
and 270,342 
controls 
combined 
9,254 cases 
and 18,386 
controls 
OR per 
SD 
European 
Two-
sampl
e 
IVW (combining 
estimate with 
those from May-
Wilson et al 2017) 
1.10(1.01, 
1.19) 
0.034* 
IVW estimate without combining with data from 
other study (May-Wilson et al 2017) 
No Unknown 
Liyanage UE, 
2019 
Plasma AA 20:4n-
6 
/ 
8,631 
participants 
White 
adults 
33.07 
4,545 cases 
and 270,342 
controls 
combined 
9,254 cases 
and 18,386 
controls 
OR per 
SD 
European 
Two-
sampl
e 
IVW (combining 
estimate with 
those from May-
Wilson et al 2017) 
1.05(1.03, 
1.07) 
2.00E-
05* 
IVW estimate without combining with data from 
other study (May-Wilson et al 2017) 
No Evidence of causality 
May-Wilson S, 
2017 
Plasma DGLA 
(20:3n-6) (GRS) 
Limited power 
(not specified) 
38,000 parti
cipants 
European 
2-11.1 
per SNP 
9,254 cases 
and 18,386 
controls 
OR per 
SD 
European 
Two-
sampl
e 
Meta-analysis of 
statistics for each 
specific fatty acid 
generated for 
each CRC cohort 
was combined 
under fixed-
effects models 
0.91(0.83, 
1.00) 
0.060 
Where more than one instrument variant was 
available: heterogeneity assessment, random-
effects inverse-variance weighted MR; assessing 
impact of pleiotropy by using IVW and MR-Egger 
methods 
No Unknown 
Liyanage UE, 
2019 
Plasma LA 18:2n-
6 
/ 
8,631 
participants 
White 
adults 
8.3 
4,545 cases 
and 270,342 
controls 
combined 
9,254 cases 
and 18,386 
controls 
OR per 
SD 
European 
Two-
sampl
e 
IVW (combining 
estimate with 
those from May-
Wilson et al 2017) 
0.95(0.93, 
0.97) 
9.60E-
05* 
IVW estimate without combining with other study No Evidence of causality 
May-Wilson S, 
2017 
Plasma Oleic acid 
(18:1n-9) (GRS) 
Limited power 
(not specified) 
38,000 parti
cipants 
European 
0.32-2.14 
per SNP 
9,254 cases 
and 18,386 
controls 
OR per 
SD 
European 
Two-
sampl
e 
Meta-analysis of 
statistics for each 
specific fatty acid 
generated for 
each CRC cohort 
was combined 
under fixed-
effects models 
0.77(0.65, 
0.92) 
0.004 
Where more than one instrument variant was 
available: heterogeneity assessment, random-
effects IVW MR; assessing impact of pleiotropy by 
using IVW and MR-Egger methods 
Yes Evidence of causality 
May-Wilson S, 
2017 
Plasma 
Palmitoleic acid 
(16:1n-7) (GRS) 
Limited power 
(not specified) 
38,000 parti
cipants 
European 
0.01-1.57 
per SNP 
9,254 cases 
and 18,386 
controls 
OR per 
SD 
European 
Two-
sampl
e 
Meta-analysis of 
statistics for each 
specific fatty acid 
0.36(0.15, 
0.84) 
0.018 
Where more than one instrument variant was 
available: heterogeneity assessment, random-
No Unknown 
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generated for 
each CRC cohort 
was combined 
under fixed-
effects models 
effects IVW MR; assessing impact of pleiotropy by 
using IVW and MR-Egger methods 
Liyanage UE, 
2019 
Plasma ALA 
18:3n-3 
/ 
8,866 partici
pants 
European 1.03 
4,545 cases 
and 270,342 
controls 
combined 
9,254 cases 
and 18,386 
controls 
OR per 
SD 
European 
Two-
sampl
e 
Wald-type ratio 
estimator 
(combining 
estimate with 
those from May-
Wilson et al 2017) 
0.89(0.78, 
1.02) 
0.098* IVW estimate without combining with other study No Unknown 
Cornish AJ, 2019 HDL 
1.000|OR≤0.75 
or OR≥1.33 
188,577 
participants 
European 6.1 
26,397 cases 
and 41,481 
controls 
OR per 
SD 
European 
Two-
sampl
e 
Maximum 
likelihood 
1.03 (0.92, 
1.14) 
0.620** 
Weighted median, mode-based estimates, MR-
Egger, leave-one-out analysis 
No Unknown 
Cornish AJ, 2019 LDL 
1.000|OR≤0.75 
or OR≥1.33 
188,577 
participants 
European 7.9 
26,397 cases 
and 41,481 
controls 
OR per 
SD 
European 
Two-
sampl
e 
Maximum 
likelihood 
1.14 (1.04, 
1.25) 
0.006** 
Weighted median, mode-based estimates, MR-
Egger, leave-one-out analysis 
No Likely non-causal 
Cornish AJ, 2019 
Mono-
unsaturated fatty 
acids 
0.493|OR≤0.75 
or OR≥1.33 
24,925 
participants 
European 0.3 
26,397 cases 
and 41,481 
controls 
OR per 
SD 
European 
Two-
sampl
e 
Wald ratio 
1.07 (0.78, 
1.46) 
0.672** 
Weighted median, mode-based estimates, MR-
Egger, leave-one-out analysis 
No Unknown 
Cornish AJ, 2019 
Omega-6 
polyunsaturated 
fatty acids 
1.000|OR≤0.75 
or OR≥1.33 
24,925 
participants 
European 2.4 
26,397 cases 
and 41,481 
controls 
OR per 
SD 
European 
Two-
sampl
e 
Maximum 
likelihood 
1.15 (0.98, 
1.36) 
0.095** 
Weighted median, mode-based estimates, MR-
Egger, leave-one-out analysis 
No Likely non-causal 
Cornish AJ, 2019 Total cholesterol 
1.000|OR≤0.75 
or OR≥1.33 
24,925 
participants 
European 9.5 
26,397 cases 
and 41,481 
controls 
OR per 
SD 
European 
Two-
sampl
e 
Maximum 
likelihood 
1.09 (1.01, 
1.18) 
0.025** 
Weighted median, mode-based estimates, MR-
Egger, leave-one-out analysis 
No Likely non-causal 
Cornish AJ, 2019 Total triglycerides 
1.000|OR≤0.75 
or OR≥1.33 
188,577 
participants 
European 6.1 
26,397 cases 
and 41,481 
controls 
OR per 
SD 
European 
Two-
sampl
e 
Maximum 
likelihood 
0.93 (0.84, 
1.04) 
0.192** 
Weighted median, mode-based estimates, MR-
Egger, leave-one-out analysis 
No Unknown 
Inflammatory Markers 
Wang X, 2018 
C-reactive protein 
(19 SNPs) 
0.825|OR≥1.12 
66,185 & 
40,473 
participants 
European 5 
30,480 cases 
and 22,844 
controls 
OR per 
SD 
European 
Two-
sampl
e 
IVW 
1.04(0.97, 
1.12) 
0.256 
Subgroup analyses stratified by cancer sites and 
stages, sex, BMI, smoking, NSAID use, aspirin use, 
history of endoscopy, family history of CRC; Egger 
regression 
No Unknown 
Cornish AJ, 2019 
Plasma IL-6 
receptor subunit 
alpha 
1.000|OR≤0.75 
or OR≥1.33 
3,301 
participants 
European 60.4 
26,397 cases 
and 41,481 
controls 
OR per 
SD 
European 
Two-
sampl
e 
Wald ratio 
0.98 (0.96, 
1.00) 
0.035** 
Weighted median, mode-based estimates, MR-
Egger, leave-one-out analysis 
No Unknown 
Insulin related markers 
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Cornish AJ, 2019 Fasting glucose 
1.000|OR≤0.75 
or OR≥1.33 
96,496 
participants 
European 3.6 
26,397 cases 
and 41,481 
controls 
OR per 
SD 
European 
Two-
sampl
e 
Maximum 
likelihood 
1.04 (0.92, 
1.18) 
0.519** 
Weighted median, mode-based estimates, MR-
Egger, leave-one-out analysis 
No Unknown 
Cornish AJ, 2019 Fasting proinsulin 
1.000|OR≤0.75 
or OR≥1.33 
46,186 
participants 
European 6.1 
26,397 cases 
and 41,481 
controls 
OR per 
SD 
European 
Two-
sampl
e 
Maximum 
likelihood 
0.97 (0.90, 
1.03) 
0.310** 
Weighted median, mode-based estimates, MR-
Egger, leave-one-out analysis 
No Unknown 
Cornish AJ, 2019 HbA1C levels 
0.999|OR≤0.75 
or OR≥1.33 
46,368 
participants 
European 1.8 
26,397 cases 
and 41,481 
controls 
OR per 
SD 
European 
Two-
sampl
e 
Maximum 
likelihood 
1.02 (0.85, 
1.22) 
0.866** 
Weighted median, mode-based estimates, MR-
Egger, leave-one-out analysis 
No Unknown 
Cornish AJ, 2019 Plasma IGF−I 
0.995|OR≤0.75 
or OR≥1.33 
3301 
participants 
European 1.4 
26,397 cases 
and 41,481 
controls 
OR per 
SD 
European 
Two-
sampl
e 
Wald ratio 
0.88 (0.76, 
1.01) 
0.064** 
Weighted median, mode-based estimates, MR-
Egger, leave-one-out analysis 
No Unknown 
Other Biomarkers 
Haycock PC, 2017 Telomere length 1 
9,190 
participants 
European / 
14,537 cases 
and 16,922 
controls 
OR per 
SD 
European 
Two-
sampl
e 
Maximum 
likelihood 
1.09(0.91, 
1.31) 
0.340 Heterogeneity analysis, weighted median, MR-Egger No Likely non-causal 
Protein& amino acid 
Au Yeung SL, 
2019 
GDF-15 
0.8|OR≥1.11 
(R2=0.15) or 
OR≥1.10 
(R2=0.21) 
5,440 
participants 
European 15 or 21 
4,562 cases 
and 382,756 
controls 
OR per 
SD 
European 
Two-
sampl
e 
IVW (Fixed effect) 
0.91(0.80, 
1.04) 
/ 
Multiplicative random effect IVW; Lead SNP 
analysis; MR-Egger intercept test; Mendelian 
randomisation restricted to instruments from the 
same gene region (PGPEP1 or GDF15)  
No Unknown 
Nimptsch K, 2017 
Adiponectin 
(Incorporating the 
ADIPOQ allele 
score and plasma 
adiponectin 
concentrations) 
0.8|OR≤0.76 
2,880 
participants 
European 
and US 
/ 
1,253 cases 
and 1,627 
controls 
OR per 
score 
unit 
European 
and US 
One-
sampl
e 
Conditional 
logistic regression 
0.73(0.40, 
1.34) 
/ 
Restriction to Caucasians; Effect estimate in 
different study (HPFS and NHS) 
No Likely non-causal 
Cornish AJ, 2019 Blood carnitine 
1.000|OR≤0.75 
or OR≥1.33 
7,824 
participants 
European 13.9 
26,397 cases 
and 41,481 
controls 
OR per 
SD 
European 
Two-
sampl
e 
Maximum 
likelihood 
0.99 (0.92, 
1.06) 
0.682** 
Weighted median, mode-based estimates, MR-
Egger, leave-one-out analysis 
No Unknown 
Cornish AJ, 2019 Blood methionine 
0.676|OR≤0.75 
or OR≥1.33 
7,824 
participants 
European 0.4 
26,397 cases 
and 41,481 
controls 
OR per 
SD 
European 
Two-
sampl
e 
Wald ratio 
0.92 (0.70, 
1.19) 
0.505** 
Weighted median, mode-based estimates, MR-
Egger, leave-one-out analysis 
No Unknown 
Cornish AJ, 2019 
Circulating 
adiponectin 
1.000|OR≤0.75 
or OR≥1.33 
39,883 
participants 
European 1.8 
26,397 cases 
and 41,481 
controls 
OR per 
SD 
European 
Two-
sampl
e 
Maximum 
likelihood 
0.93 (0.81, 
1.07) 
0.309** 
Weighted median, mode-based estimates, MR-
Egger, leave-one-out analysis 
No Unknown 
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Cornish AJ, 2019 
Circulating fetuin-
A 
1.000|OR≤0.75 
or OR≥1.33 
9,055 & 
2,119 
participants 
European, 
African 
American 
14.3 
26,397 cases 
and 41,481 
controls 
OR per 
SD 
European 
Two-
sampl
e 
Wald ratio 
0.98 (0.94, 
1.02) 
0.370** 
Weighted median, mode-based estimates, MR-
Egger, leave-one-out analysis 
No Unknown 
Cornish AJ, 2019 
Serum 
immunoglobulin E 
0.997|OR≤0.75 
or OR≥1.33 
6,819 
participants 
European 1.6 
26,397 cases 
and 41,481 
controls 
OR per 
SD 
European 
Two-
sampl
e 
Maximum 
likelihood 
0.92 (0.82, 
1.03) 
0.159** 
Weighted median, mode-based estimates, MR-
Egger, leave-one-out analysis 
No Unknown 
*: statistically significant threshold set up at P≤0.0001; **: statistically significant threshold set up at P≤0.0013, GI: genetic instrument, SNP: Single Nucleotide Polymorphism, OR: odds ratio, HR: hazard ratio, SD: standard deviation, GRS: genetic risk score, BMI: body mass index, IVW: inverse variance weighted, EPA: 
Eicosapentaenoic acid, DHA: Docosahexaenoic acid, DPA: Docosapentaenoic acid, AA: arachidonic acid, DGLA: dihomo-γ-linolenic acid, LA: linoleic acid, ALA: α-Linolenic acid, HDL: high-density lipoprotein cholesterol, LD: linkage disequilibrium, LDL: low-density lipoprotein cholesterol, IL-6: interleukin 6, HbA1C: glycated 
hemoglobin, IGF-1: insulin-like growth factor 1, GDF-15: Growth differentiation factor 15. 
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Supplementary Table 4 General characteristics of 145 meta-analyses of observational studies 
First author/Year 
(citation) Population Location Biomarker 
No of 
cases 
No of 
participants 
Unit of 
comparison 
No of 
studies 
Study 
design Metric Model Effect size (95%CI) 
Fatty acid/Lipid metabolism biomarkers 
Yang B,20141 CRC & controls America Europe Asia Adipose DHA 22:6 (n-3) 93 204 Mean (% total fatty acids) 2 CC SMD Random 0.19(-0.09, 0.47) 
Yang B,20141 CRC & controls America Europe Asia Adipose DPA 22:5 (n-3) 93 204 Mean (% total fatty acids) 2 CC SMD Random -0.02(-0.35, 0.30) 
Yang B,20141 CRC & controls America Europe Asia Adipose EPA 20:5 (n-3) 93 204 Mean (% total fatty acids) 2 CC SMD Random -0.07(-0.35, 0.20) 
Yang B,20141 General/CRC & controls America Europe Asia Biospecimen DHA 22:6 (n-3) 1,315 84,114 
Highest vs lowest 
categories 6 CC/CS RR Random 0.68(0.54, 0.84) 
Yang B,20141 CRC & controls America Europe Asia Biospecimen DHA 22:6 (n-3) 623 1,938 Mean (% total fatty acids) 7 CC SMD Random -0.23(-0.34, -0.11) 
Yang B,20141 General/CRC & controls America Europe Asia Biospecimen DHA 22:6 (n-3) 675 58,713 
Highest vs lowest 
categories 3 CS RR Random 0.76(0.56, 1.01) 
Yang B,20141 General/CRC & controls America Europe Asia Biospecimen DPA 22:5 (n-3) 446 15,593 
Highest vs lowest 
categories 3 CC/CS OR Random 0.80(0.42, 1.52) 
Yang B,20141 CRC & controls America Europe Asia Biospecimen DPA 22:5 (n-3) 587 1,404 Mean (% total fatty acids) 6 CC SMD Random -0.08(-0.22, 0.06) 
Yang B,20141 General/CRC & controls America Europe Asia Biospecimen EPA 20:5 (n-3) 1,367 84,223 
Highest vs lowest 
categories 6 CC/CS RR Random 0.78(0.64, 0.96) 
Yang B,20141 CRC & controls America Europe Asia Biospecimen EPA 20:5 (n-3) 623 1,938 Mean (% total fatty acids) 7 CC SMD Random -0.27(-0.41, -0.13) 
Yang B,20141 General/CRC & controls America Europe Asia Biospecimen EPA 20:5 (n-3) 675 58,713 
Highest vs lowest 
categories 3 CS RR Random 0.77(0.58, 1.00) 
Yang B,20141 General/CRC & controls America Europe Asia Biospecimens LC n-3 PUFA 1,502 60,360 
Highest vs lowest 
categories 7 CC/CS RR Random 0.74(0.63, 0.87) 
Yang B,20141 CRC & controls America Europe Asia Biospecimens LC n-3 PUFA 329 786 Mean (% total fatty acids) 4 CC SMD Random 0.22(0.07, 0.37) 
Yang B,20141 General/CRC & controls America Europe Asia Biospecimens LC n-3 PUFA 675 58,713 
Highest vs lowest 
categories 3 CS RR Random 0.76(0.59, 0.97) 
Yang B,20141 CRC & controls America Europe Asia Blood DHA 22:6 (n-3) 646 1,425 Mean (% total fatty acids) 5 CC SMD Random -0.24(-0.40, -0.10) 
Yang B,20141 CRC & controls America Europe Asia Blood DPA 22:5 (n-3) 646 1,425 Mean (% total fatty acids) 4 CC SMD Random 0.04(- 0.11,0.20) 
Yang B,20141 CRC & controls America Europe Asia Blood EPA 20:5 (n-3) 283 564 Mean (% total fatty acids) 5 CC SMD Random -0.30(-0.44, -0.15) 
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Esposito K,20132 General/CRC & controls America Europe Asia HDL-cholesterol 1,335 / 
Highest vs lowest 
categories (mg/dl) 9 CC/CS RR Random 0.89(0.78, 1.02) 
Yao X,20153 General/CRC & controls 
North America, 
Europe, and Asia HDL-cholesterol 2,542 136,698 
Highest vs lowest 
categories 6 PS RR Random 0.84(0.69, 1.02) 
Yao X,20153 General/CRC & controls 
North America, 
Europe, and Asia LDL-cholesterol 1,626 9,175 
Highest vs lowest 
categories 3 PS RR Random 1.04(0.60, 1.81) 
Yao X,20153 General/CRC & controls 
North America, 
Europe, and Asia Total cholesterol 10,892 7,725,310 
Highest vs lowest 
categories 10 PS RR Random 1.11(1.01, 1.21) 
Yao X,20153 General/CRC & controls 
North America, 
Europe, and Asia Total cholesterol / / 
100 mg/dL 
increment 5 PS RR Random 1.01(0.97, 1.05) 
Esposito K,20132 General/CRC & controls America Europe Asia Triglycerides 8,164 / 
Highest vs lowest 
categories (mg/dl) 13 CC/CS RR Random 1.06(0.95, 1.17) 
Yao X,20153 General/CRC & controls 
North America, 
Europe, and Asia Triglycerides 8,127 2,252,217 High versus low 9 PS RR Random 1.18(1.04, 1.34) 
Yao X,20153 General/CRC & controls 
North America, 
Europe, and Asia Triglycerides / / 
50 mg/dL 
increment 3 PS RR Fixed 1.01(1.00, 1.03) 
Infectious agents 
Repass J,20184 
CRC patients 
(CRC sample 
with normal 
tissue) 
North America F. nucleatum  139 139 
CRC tissue to 
adjacent normal 
tissue  
2 CC r Random 0.38(0.17, 0.56) 
Liu C,201620 
H.pylori-
infected 
patients and 
controls 
America Europe Asia H. pylori infection  5,380 17,189 CRC vs non-CRC 19 NCC/CC/CSS OR Random 1.57(1.29, 1.83) 
Wang F,20146 CRC & Controls America Europe Asia H. pylori infection  3,450 10,808 Infected vs non-infected 17 CC OR Fixed 1.28(1.16, 1.41) 
Wang F,20146 CRC & Controls America Europe Asia H. pylori infection_CagA / / CRC vs non-CRC 6 CC OR Fixed 1.22(1.08, 1.37) 
Wang X,20177 H.pylori infected and controls / H. pylori infection 3,300 16,857 CRC vs non-CRC 10 CC/CSS OR Random 1.29(1.06, 1.51) 
Zhao Y,20168 CRC & Controls America Europe Asia Australia H. pylori infection 1,457 3,762 CRC vs non-CRC 14 CC OR Random 1.33(1.01, 1.77) 
Wu Q,20139 CRC & Controls America Europe Asia H. pylori infection 3,488 7,836 CRC vs non-CRC 20 CC/NCC/CSS OR Random 1.39(1.18, 1.64) 
Rokkas T,201310 CRC & Controls America Europe Asia H. pylori infection / / Infected vs non-infected 17 CC/CSS OR Random 1.30(1.07, 1.59) 
Guo Y,201411 CRC & Controls Asia H. pylori infection / / Infected vs non-infected 
 CC OR Random 1.08(0.89, 1.68) 
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Zhao YS, 200812 CRC & Controls America Europe Asia H. pylori infection 1,709 3,581 CRC vs controls 14 CC/NCC OR Random 1.49(1.17, 1.91) 
Baandrup L,201713  
CRC/CRA tissue 
and tumour 
adjacent tissue 
or cancer free 
control tissue 
America Europe Asia HPV  699 1,156 Tumour tissue vs normal tissue 8 CC OR Random 2.10(1.30, 3.20) 
Baandrup L,201713  
CRC/CRA tissue 
and tumour 
adjacent tissue 
or cancer free 
control tissue 
America Europe Asia HPV  419 575 Infected vs non-infected 8 CC OR Random 6.00(2.00, 17.90) 
Damin DC,201314 CRC & controls America Europe Asia HPV 289 393 Infected vs non-infected 5 CC OR Random 10.04(3.67, 27.46) 
Damin DC,201314 CRC & Controls America Europe Asia HPV / / Tumour tissue vs normal tissue 6 CC OR Random 4.05(1.79, 9.14) 
Pelizzer T,201615 HPV & Controls America Europe Asia HPV 126 612 CRC vs non-CRC 4 CC/CSS OR Random 4.66(2.50, 8.69) 
Zhang XH,201816 CRC & Controls China HPV 766 1,236 Tumour tissue vs normal tissue 10 CC OR Random 10.78(4.22, 27.53) 
Peder LD,201817 CRC & Controls Brazil HPV 216 / Infected vs control 2 CC RR Random 2.03(1.77, 2.33) 
Ibragimova 
MK,201818 CRC & Controls America Europe Asia HPV 2,049 2,879 
Tumour tissue vs 
Cancer-free tissue 19 CC RR Random 2.97(1.42, 6.22) 
Bai B,201619 CRC patients America Europe Asia Human cytomegalovirus infection 480 960 
Tumour tissue vs 
normal tissue 4 CC OR Fixed 6.59(4.48, 9.69) 
Liu H,20165 CRC & Controls Europe Asia Bacteroides-Prevotella group 97 255 
Healthy controls 
(logarithmic 
number of 
bacteria per gram 
stool) 
3 CC SMD Random -0.71(-2.56, 1.14) 
Liu H,20165 CRC & Controls Europe Asia Bifidobacterium 127 315 
Healthy controls 
(logarithmic 
number of 
bacteria per gram 
stool) 
4 CC SMD Random -3.3(-6.57, -0.03) 
Liu H,20165 CRC & Controls Europe Asia Enterobacteriaceae 37 76 
Healthy controls 
(logarithmic 
number of 
bacteria per gram 
stool) 
2 CC SMD Random 2.69(0.66, 4.72) 
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Liu H,20165 CRC & Controls Europe Asia Escherichia coli 90 239 
Healthy controls 
(logarithmic 
number of 
bacteria per gram 
stool) 
2 CC SMD Random 1.4(-1.38, 4.18) 
Liu H,20165 CRC & Controls Europe Asia Faecalibacterium prausnitzii 86 233 
Healthy controls 
(logarithmic 
number of 
bacteria per gram 
stool) 
3 CC SMD Random -0.33(-0.6, 0.05) 
Liu H,20165 CRC & Controls Europe Asia Lactobacillus 127 315 
Healthy controls 
(logarithmic 
number of 
bacteria per gram 
stool) 
4 CC SMD Random -2.72(-5.94, 0.50) 
Liu H,20165 CRC & Controls Europe Asia Total bacteria 86 233 
Healthy controls 
(logarithmic 
number of 
bacteria per gram 
stool) 
3 CC SMD Random 0.23(-0.54, 1.00) 
Boleij A,201121 
S. bovis–
infected 
patients  
/ Streptococcus bovis 189 340 CRC vs non-CRC 6 case-series OR Fixed 7.26(3.94, 13.36) 
Krishnan S,201422 CRC & controls / Streptococcus bovis in faeces 148 414 / 3 CC OR Random 2.46(0.72, 8.46) 
Inflammatory Markers 
Guo YZ,201323 General America Europe CRP 1,140 135,794 Per natural log unit change 7 CS HR Random 1.10(0.97, 1.23) 
Zhou B,201424 General/CRC & controls America Europe Asia CRP 4,779 152,942 
1-unit change in 
ln(mg/l) 17 
CS/NC
C RR Random 1.12(1.05, 1.21) 
Tsilidis KK, 200825 General/CRC & controls America Europe Asia CRP 1,159 39,145 
1-unit increase in 
ln-transformed 
(mg/L) 
8 NCC/CS OR Random 1.12(1.01, 1.25) 
Zhou B,201424 General/CRC & controls America Europe Asia  IL-6 1,125 9,909 
1-unit change in 
ln (pg/ml) 6 
CS/NC
C RR Random 1.10(0.88, 1.36) 
Kakourou A,201526  General/CRC & controls America Europe  IL-6 1,308 9,728 
Per 1 U change in 
ln pg/mL 7 
CC/CS/
NCC RR Random 1.10(0.94, 1.28) 
Insulin related biomarkers 
Xu J,201627 CRC & Controls America Europe Asia C peptide  3,191 1,375,980 Highest vs lowest categories(ng/ml) 9 
CC/NC
C RR Random 1.27(1.08, 1.49) 
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Pisani, 200828 General/CRC & controls / C peptide  1,309 5,542 
Highest vs lowest 
categories 12 
CC/NC
C/CS RR Fixed 1.35(1.13, 1.61) 
Chen L,201329 CRC & Controls America Europe Asia C peptide  3,109 7,394 Highest vs lowest categories 9 NCC OR Random 1.39(1.04, 1.87) 
Xu J,201627 General/CRC & controls America Europe Asia HbA1c 2,137 820,317 
Highest vs lowest 
categories (%) 8 
CC/NC
C/CS RR Fixed 1.22(1.02, 1.47) 
Xu J,201627 General/CRC & controls America Europe Asia HOMA-IR  2,956 347,326 
Highest vs lowest 
categories (fasting 
glucose (mmol/L) 
× fasting insulin 
(mIU/L) / 22.5) 
8 CC/NCC/CS OR Fixed 1.47(1.24, 1.74) 
Xu J,201627 General/CRC & controls America Europe Asia Fasting insulin  3,239 354,870 
Highest vs lowest 
categories 
(mIU/L) 
10 CC/NCC/CS OR Fixed 1.42(1.19, 1.69) 
Xu J,201627 General/CRC & controls America Europe Asia Fasting glucose  17,764 3,805,861 
Highest vs lowest 
categories 
(mmol/L) 
18 CC/NCC/CS OR Random 1.12(1.06, 1.18) 
Shi J,201530 General/CRC & controls / Fasting glucose  62,814 2,969,306 
Per 20 mg/dL 
increase  6 
CC/CS/
NCC RR Fixed 1.02(1.01, 1.02) 
Shi J,201530 General/CRC & controls / Fasting glucose  62,814 2,969,306 
Highest vs lowest 
categories (FPG 
category ≥ 3)  
6 CC/CS/NCC RR Fixed 1.15(1.02, 1.31) 
Shi J,201530 General/CRC & controls / Fasting glucose  / / 
Highest vs lowest 
categories (FPG 
category ≥=2)  
5 CC/CS/NCC RR Random 1.57(1.31, 1.89) 
Crawley DJ,201431 / America Europe Asia Fasting glucose  908 / 
‘high’ and 
‘normal’   <6.1 
mmol/L cut off 
5 CC/CS RR Random 1.35(1.21, 1.51) 
Pisani, 200828 General/CRC & controls / Fasting glucose  1,741 1,381,741 
Highest vs lowest 
categories 11 
CC/NC
C/CS RR Fixed 1.18(1.07, 1.31) 
Chi F,201332  CRC & Controls Caucasians, Asian, mixed population IGF 1 3,807 11,613 
Highest vs lowest 
categories 16 
CC/NC
C OR Fixed 1.25(1.08, 1.45) 
Rinaldi S,201033 CRC & Controls Europe IGF I 1,741 5,586 
1 standard 
deviation change 
of average IGF-I 
distribution  
10 CC/CS RR Random 1.10(1.01, 1.19) 
Morris J, 200634 CRC & Controls America, Europe, Asia IGF 1 1,106 3,501 Highest vs lowest categories 7 NCC OR Random 1.37(1.05, 1.78) 
Chi F,201332  CRC & Controls Caucasians, Asian, mixed population IGF 2 783 4,007 
Highest vs lowest 
categories 6 
CC/NC
C OR Fixed 1.52(1.16, 2.01) 
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Morris J, 200634 CRC & Controls America, Europe, Asia IGF 2 384 1,685 Highest vs lowest categories 3 NCC OR Random 1.95(1.26, 3.00) 
Chi F,201332 CRC & Controls Caucasians, Asian, mixed population IGFBP 1 2,154 6,439 
Highest vs lowest 
categories 7 
CC/NC
C OR Fixed 0.85(0.70, 1.03) 
Chi F,201332  CRC & Controls Caucasians, Asian, mixed population IGFBP 2 1,348 2,962 
Highest vs lowest 
categories 3 
CC/NC
C OR Random 0.77(0.41, 1.43) 
Chi F,201332  CRC & Controls Caucasians, Asian, mixed population IGFBP 3 3,755 11,509 
Highest vs lowest 
categories 15 
CC/NC
C OR Random 0.88(0.71, 1.10) 
Morris J, 200634 CRC & Controls America, Europe, Asia IGFBP 3 1,106 3,501 Highest vs lowest categories 7 NCC OR Random 0.98(0.64, 1.51) 
Micronutrients 
Chuang SC,201335 CRC & Controls America Europe Folate 3,477 10,516 Dose-response (per 10 nmol/L )  8 CS RR Fixed 0.94(0.88, 1.01) 
Chuang SC,201335 CRC & Controls America Europe Folate 3,477 10,516 Highest vs lowest categories 8 CS RR Fixed 0.91(0.77, 1.05) 
Shiao SPK,201836 CRC & Controls Europe, Asia Folate 1,466 3,393 Mean (nmol/L) 8 CC SMD Random -0.46(-0.92, -0.00) 
Shiao SPK,201836 CRC & Controls Europe, Caucasian, Asia Folate 3,515 8,764 Mean (nmol/L) 9 CS SMD Random 0.01(-0.06, 0.08) 
Moazzen S,201737 CRC & Controls / Folate  / / / 22 CC RR Random 0.85(0.85, 1.30) 
Zhang D, 201538 CRC & Controls / Folate 1,181 3,139 CRC vs healthy controls 11 CC SMD Random -1.10(-1.60, -0.60) 
Shiao SPK,201836 CRC & Controls Europe, Asia Vitamin B12   360 1,068 Mean (pmol/L) 6 CC SMD Random -0.99(-1.74, 0.25) 
Shiao SPK,201836 CRC & Controls Europe, Caucasian Vitamin B12   3,299 8,309 Mean (pmol/L) 8 CS SMD Random -0.04(-0.09, 0.00) 
Sun NH,201639 CRC & Controls Europe USA Vitamin B12   / / Per 150 pmol/l increment  3 CC RR Random 1.02(0.88, 1.19) 
Sun NH,201639 CRC & Controls Europe USA Vitamin B12   682 1,732 Highest vs lowest categories 3 CC RR Fixed 0.93(0.56, 1.53) 
Zhang D, 201538 CRC & Controls / Vitamin B12   873 2,198 CRC vs healthy controls 10 CC OR Random 
-28.52(-50.60, -
6.43) 
Shiao SPK,201836 CRC & Controls Globe Vitamin B2  1,643 4,240 Mean (nmol/L) 3 CS SMD Random 0.00(-0.05, 0.07) 
Ben S, 201840 General/CRC & controls Europe Vitamin B2  1,593 32,962 
Highest vs lowest 
categories 2 NCC RR Fixed 0.74(0.59, 0.92) 
Shiao SPK,201836 CRC & Controls Globe Vitamin B6  2,658 7,361 Mean (nmol/L) 5 CS SMD Random -0.06(-0.11, 0.01) 
Larsson SC,201041 General America Europe Vitamin B6  883 2,207 Highest vs lowest categories (pmol/) 4 PS RR Random 0.52(0.38, 0.71) 
Larsson SC,201041 General America Europe Vitamin B6  883 2,207 100pmol/mL increment 4 PS RR Random 0.51(0.38, 0.69) 
Mocellin S,201742  CRC & Controls Europe USA Vitamin B6  425 / Highest vs lowest categories 5 RS RR Random 0.56(0.46, 0.67) 
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Mocellin S,201742 CRC & Controls Europe USA Vitamin B6  2,203 / Per 100 nmol/L decrease  5 RS RR Random 0.52(0.43, 0.64) 
Vinceti M,201443 General US Netherlands Finland selenium 762 383,137 
Highest vs lowest 
categories 5 
CS/NC
C OR Random 0.89(0.65, 1.23) 
Vinceti M,201844 General Europe USA selenium 2,627 712,746 Highest vs lowest categories 5 
CS/NC
C OR / 0.82(0.72, 0.94) 
Chung M,201145 General/CRC & controls / 25-hydroxyvitamin D  1,127 2,249 
Per 10-nmol/L 
increase  9 NCC OR Random 0.94(0.91, 0.97) 
Ekmekcioglu 
C,201746 CRC & Controls Europe USA 25-hydroxyvitamin D  / / 
20–30 ng/mL 
25(OH)D status vs 
those in the 
lowest category  
24 CC/CS RR Fixed 0.83(0.76, 0.90) 
Ekmekcioglu 
C,201746 CRC & Controls Europe USA 25-hydroxyvitamin D  / / 
Highest vs lowest 
categories 24 CC/CS RR Fixed 0.62(0.56, 0.70) 
Gandini S,201147 General/CRC & controls Europe USA 25-hydroxyvitamin D  2,630 / 10 ng/ml increase 9 
CC/NC
C SRR Random 0.85(0.79, 0.91) 
Garland CF,201748 CRC & Controls / 25-hydroxyvitamin D  6,691 175,127 Highest vs lowest categories 15 NCC OR Random 0.67(0.59, 0.76) 
Ma Y,201149 CRC & controls America Europe Asia 25-hydroxyvitamin D  3,142 7,840 Highest vs lowest categories 9 
CS/NC
C RR Random 0.67(0.54, 0.80) 
Ma Y,201149 CRC & controls America Europe Asia 25-hydroxyvitamin D  2,767 6,715 10 ng/mL increment 9 
CS/NC
C RR Random 0.74(0.63, 0.89) 
Touvier M,201150 CRC & Controls / 25-hydroxyvitamin D  2,318 / Per 100 IU/L increment 6 NCC RR Random 0.96(0.94, 0.97) 
Lee JE,201151 CRC & Controls America Europe Asia 25-hydroxyvitamin D  2,622 6,560 Highest vs lowest categories 9 PS OR Random 0.66(0.54, 0.81) 
Lee JE,201151 CRC & Controls America Europe 1,25-dihydroxyvitamin D 625 1,801 Highest vs lowest categories 4 PS OR Random 1.01(0.59, 1.73) 
Yin L, 200952 General/CRC & controls America Europe Asia 25-hydroxyvitamin D  984 2,944 
Per 20 ng ⁄mL 
increase in serum 
25(OH)D 
7 NCC/CS OR Random 0.57(0.43, 0.76) 
Dong Y,201753 General/CRC & controls Caucasian Asian Vitamin E 520 6,440 Mean (µmol/L) 10 CC WMD Random -3.00(-4.40, -1.59) 
Gumulec J,201454 CRC & Controls / Serum Zinc  313 529 
Largest variation 
among serum 
levels  
5 CC SMD Random 0.04(-2.57, 2.64) 
Gumulec J,201454 CRC & Controls / Tissue Zinc 234 398 
Largest variation 
among tissue 
levels  
7 CC SMD Random 0.37(-0.97, 1.72) 
Other Biomarkers 
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Jiang R,201655 CRC & Controls Canada Europe Asia Enterolactone 762 2,408 Per doubling (nmol/l) 3 PS RR Random 1.04(0.98, 1.10) 
Zhang BL,201556 General/CRC & controls / Blood group A 6,931 3,214,941 A vs non-A 8 CC/CS OR Fixed 1.05(0.98, 1.13) 
Zhang BL,201556 General/CRC & controls / Blood group AB 6,931 3,191,289 AB vs non-AB 8 CC/CS OR Random 1.07(0.88, 1.26) 
Zhang BL,201556 General/CRC & controls / Blood group B 6,931 3,193,532 B vs non-B 8 CC/CS OR Random 1.12(0.94, 1.29) 
Zhang BL,201556 General/CRC & controls / Blood group O 6,931 3,219,151 O vs non-O 8 CC/CS OR Random 0.89(0.81, 0.96) 
Zhang X,201757 General Europe, North America Telomere Length 319 / 
Longest or 
shortest TL group 2 PS OR Random 1.01(0.68, 1.50) 
Naing C,201758 General/CRC & controls America Europe Asia Telomere Length 951 2,569 
Shortest Q4 vs 
longest Q1 4 NCC OR Fixed 1.01(0.77, 1.34) 
Naing C,201758 General/CRC & controls America Europe Asia Telomere Length 4,000 10,375 
Shortest Q4 vs 
longest Q1 4 CC OR Random 1.65(0.96, 2.83) 
Protein&amino acids 
Lu S,201759 CRC & Controls Caucasian Adiponectin 4,076 9,585 Highest vs lowest categories 8 NCC RR Fixed 0.81(0.71, 0.93) 
Lu S,201759 CRC & Controls Caucasian Adiponectin 4,076 9,585 
Per 5 µg/mL 
increase (dose 
reponse) 
8 NCC RR Fixed 0.86(0.77, 0.95) 
Lu W,201860 CRC & Controls / Adiponectin 7,554 17,352 Mean (µg/mL) 31 CC WMD Random -0.76(-1.20, -0.32) 
Xu XT,201161 CRC & Controls America Europe Asia Adiponectin 1,343 2,996 Mean (µg/mL) 11 CC/CSS/NCC WMD Random -1.08(-1.84, -0.33) 
Joshi RK,201462 CRC & Controls / Adiponectin 3,416 8,265 μg/mL 10 CC/CSS/NCC OR Random 1.03(0.72, 1.47) 
An W,201263 CRC & Controls America Europe Asia Adiponectin 488 827 Mean (µg/mL) 10 CC/NCC WMD Random -1.51(-2.42, -0.59) 
Joshi RK,201462 CRC & Controls / Adiponectin 3,416 11,681 
Reference group 
and compared 
group (μg/mL) 
9 CC/NCC/CSS OR Fixed 0.91(0.83, 1.00) 
Yu D,201864 CRC & Controls Japan UK Angiogenin  188 240 Mean (ng/ml) 2 CC SMD Random 1.54(0.50, 2.59) 
Yang G,201665 CRC & Controls / Resistin 965 3,255 Mean (ng/mL) 11 CC/CS WMD Random 1.47(0.78, 2.16) 
Joshi RK,201462 CRC & Controls / Leptin / / ng/mL 9 CC/CSS/NCC OR Random 1.36(0.95, 1.94) 
Gialamas SP,201366 CRC & Controls America Europe Asia Leptin 3,508 7,478 Mean 23 
CC/CS/
CSS/NC
C 
SMD Random 0.18(-0.04, 0.40) 
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Gialamas SP,201366 CRC & Controls Europe Asia Leptin / / Highest vs lowest categories 10 
CC/CSS
/NCC RR Random 1.04(0.65, 1.65) 
Joshi RK,201462 CRC & Controls / Leptin 2,597 6,077 
Reference group 
and compared 
group (ng/mL) 
8 CC/NCC/CSS OR Random 1.06(0.87, 1.28) 
Feng Z, 201567 CRC & Controls Europe Asia Ferritin 277 927 Mean (ng/ml) 6 CC SMD Random -1.57(-2.72, -0.42) 
Shiao SPK,201836 CRC & Controls Europe, Asia Homocysteine 2,438 5,419 Mean (mmol/L) 10 CC SMD Random 0.71(0.41, 1.02) 
Shiao SPK,201836 CRC & Controls Europe, Caucasian Homocysteine 4,047 9,604 Mean (mmol/L) 8 CS SMD Random 0.11(0.02, 0.21) 
Zhang DH, 201538 CRC & Controls / Homocysteine 3,954 8,992 CRC vs healthy controls 22 CC OR Random 2.63 (1.74, 3.51) 
Shiao SPK,201836 CRC & Controls Europe Methionine  1,980 5,493 Mean (mmol/L) 2 CC SMD Random -0.29(-0.56, 0.02) 
 Sun SJ,201668 CRC & Controls Asia Caucasians Africa 
HER-2(human epidermal 
growth factor receptor 2) 
expression 
932 1,453 Categories 13 CC OR Random 10.44(5.50, 19.81) 
Xing XJ,201469 CRC & Controls Europe Asia MMP7 625 1,020 Mean (% total fatty acids) 7 CC SMD Random 2.15(1.46, 2.84) 
Li XX,201470 CRC & Controls Asian TLR-4 protein 168 283 CRC vs healthy controls 3 CC OR Random 4.75(1.16, 19.36) 
Ouyang Z,201771 CRC & Controls Asian Caucasian CD26  952 1,809 Tumour cell vs normal cell 7 CC SMD Random -0.33(-2.97, 2.30) 
Ouyang Z,201771 CRC & Controls Asian CD26  239 421 Tumour cell vs normal cell 3 CC SMD Random 3.94(1.55, 6.33) 
Ouyang Z,201771 CRC & Controls Caucasian CD26  475 1,150 Tumour cell vs normal cell 4 CC SMD Random -3.77(-7.67, 0.12) 
CRC: colorectal cancer, RR: risk ratio, SMD: standard mean difference, OR: odds ratio, r: standardized correlation coefficient, CC: case-control study, CS: cohort study, NCC: nested case-control study,  CSS: cross-
sectional study, PS: prospective study,  LC n-3 PUFA: long chain n-3 polyunsaturated fatty acid, EPA: Eicosapentaenoic acid, DHA: Docosahexaenoic acid, DPA: Docosapentaenoic acid, HDL: high-density lipoprotein 
cholesterol, LDL: low-density lipoprotein cholesterol, HPV: Human papillomavirus, CRP: C-reactive protein, IL-6: Interleukin 6, HOMA-IR: homeostatic model assessment-insulin resistance, IGF 1/2: Insulin-like growth 
factor 1/2, IGFBP 1/2/3: Insulin-like growth factor-binding protein 1/2/3, HbA1c: glycated hemoglobin, MMP7: matrix metalloproteinase-7, CD26: dipeptidyl peptidase IV. 
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Supplementary Table 5 Characteristics and main findings of 66 Mendelian randomisation analyses 
First author, Year 
(Citation) 
Biomarker (Unit) 
 
Power to 
detect given 
effect 
estimates 
Exposure Outcome 
Study 
design 
Main method Main estimate P value Sensitivity analyses 
Consistent 
evidence of a 
causal effect 
Evidence 
Sample size Population 
Variance 
(R2) 
explained 
by GI (%) 
Sample size Metric Population 
Micronutrients 
He Y,201872 
25-
hydroxyvitamin D 
(log-transformed 
nmol/L) 
0.72|OR=0.83 
2,821 
participants 
European 2.84 
10,725 cases, 
30,794 
controls 
OR per 
SD 
European 
One-
sample 
Coefficient ratio 
method 
(Weighted GRS 
adjusted age, sex 
and BMI) 
1.03(0.51,2.07) 0.931 
Without adjustment for age, sex and BMI; 
unweighted GRS 
No Unknown 
He Y,201872 
25-
hydroxyvitamin D 
(log-transformed 
nmol/L) 
0.93|OR=0.83 
77,354 
participants 
European 2.84 
18,967 
cases,48,168 
controls 
OR per 
SD 
European 
Two-
sample 
IVW 0.91(0.69,1.19) 0.475 
Weighted median, MR-Egger, robust regression, 
as well as linear regression, different 
combinations of SNPs 
No Unknown 
Chandler PD, 
201873 
25-
hydroxyvitamin D 
(GRS) 
/ 
1,782 
participants 
European 
women 
/ 
329 cases and 
23,294 
participants 
HR per 
score 
unit 
European 
women 
One-
sample 
Age-adjusted Cox-
proportional 
hazard regression 
by using 
unweighted GRS 
(continuous) 
1.06(1.00,1.13 
) 
0.070 
Categorical assessment of the GRS (0–5 
(reference group), 6–7 and 8–10 points), 
adjustment for BMI, exclusion of one SNP and 
reporting HR per 20 nmol/L increase in 25(OH)D 
No Unknown 
Dimitrakopoulou 
V, 201774 
25-
hydroxyvitamin D 
(weighted multi-
polymorphism 
score) 
≥0.8|OR≤0.85 
(OR≥1.18) 
(R2=0.05) or 
OR≤0.81 
(OR≥1.23) 
(R2=0.03) 
4501 & 
33,996 
participants 
European 3 to 5 
11488 cases 
and 11679 
controls 
OR per 
25nm
ol/L 
increa
se 
European 
Two-
sample 
IVW and 
likelihood-based 
method 
IVW: 
0.92(0.76,1.10) 
Likelihood: 
0.92 (0.76, 
1.10) 
IVW: 
0.36; 
Likelihoo
d: 0.36 
Colorectal cancer in men and women, colon 
cancer, rectal cancer, proximal colon cancer, 
distal colon cancer; MR-Egger, weighted median 
approach, and over-identification tests; Two 
separate allelic scores: vitamin D synthesis allele 
score and metabolism allele score 
No Unknown 
Dimitrakopoulou 
V, 201774 
25-
hydroxyvitamin D 
(weighted multi-
polymorphism 
score) 
≥0.8|OR≤0.85 
(OR≥1.18) 
(R2=0.05) or 
OR≤0.81 
(OR≥1.23) 
(R2=0.03) 
4501 & 
33,996 
participants 
European 3 to 5 
5100 cases and 
4831 controls 
OR per 
25nm
ol/L 
increa
se 
European 
Two-
sample 
IVW and 
likelihood-based 
method 
IVW: 1.04 
(0.78, 1.38); 
Likelihood: 
1.04 (0.78, 
1.38) 
IVW: 
0.81; 
Likelihoo
d: 0.81 
Colorectal cancer in men and women, colon 
cancer, rectal cancer, proximal colon cancer, 
distal colon cancer; MR-Egger, weighted median 
approach, and over-identification tests; Two 
separate allelic scores: vitamin D synthesis allele 
score and metabolism allele score 
No Unknown 
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Theodoratou E, 
201275 
25-
hydroxyvitamin D 
(GRS) 
<0.35 
2001 cases 
and 2237 
controls 
Scottish 3.6-5.2 
2001 cases and 
2237 controls 
OR per 
1ng/m
l 
increa
se 
Scottish 
One-
sample 
Logistic 
regression 
1.16 
(0.60,2.23) 
/ 
Unadjusted age and sex; formed three different 
allele scores 
No Unknown 
Ong JS,201876 
25-
hydroxyvitamin D 
/ 
4501 & 
33,996 & 
8,711 
participants 
European 3.5 
4,442 cases 
and 264,638 
controls 
OR per 
score 
unit 
European 
Two-
sample 
IVW 0.94(0.79,1.13) 0.520 
Meta-analysed UK-Biobank individual cancer 
estimates with those previously published using 
data from various studies and consortia 
No Unknown 
Cornish AJ, 
201977 
Blood selenium 
1.000|OR≤0.75 
or OR≥1.33 
2,603 
participants 
Queensland 2 
26,397 cases 
and 41,481 
controls 
OR per 
SD 
European 
Two-
sample 
Wald ratio 
0.85 (0.75-
0.96) 
0.008** 
Weighted median, mode-based estimates, MR-
Egger, leave-one-out analysis 
No 
Likely non-
causal 
Cornish AJ, 
201977 
Blood zinc 
1.000|OR≤0.75 
or OR≥1.33 
2,603 
participants 
Queensland 4.6 
26,397 cases 
and 41,481 
controls 
OR per 
SD 
European 
Two-
sample 
Maximum 
likelihood 
0.94 (0.86-
1.03) 
0.179** 
Weighted median, mode-based estimates, MR-
Egger, leave-one-out analysis 
No Unknown 
Cornish AJ, 
201977 
Circulating 25-
hydroxyvitamin D 
1.000|OR≤0.75 
or OR≥1.33 
79,366 
participants 
European 2.6 
26,397 cases 
and 41,481 
controls 
OR per 
SD 
European 
Two-
sample 
Maximum 
likelihood 
0.99 (0.90-
1.09) 
0.895** 
Weighted median, mode-based estimates, MR-
Egger, leave-one-out analysis 
No Unknown 
Cornish AJ, 
201977 
Circulating 
carotenoids 
1.000|OR≤0.75 
or OR≥1.33 
1,190 
participants 
Italian 2.8 
26,397 cases 
and 41,481 
controls 
OR per 
SD 
European 
Two-
sample 
Wald ratio 
1.04 (0.94-
1.15) 
0.451** 
Weighted median, mode-based estimates, MR-
Egger, leave-one-out analysis 
No Unknown 
Cornish AJ, 
201977 
Iron status 
0.981|OR≤0.75 
or OR≥1.33 
48,972 
participants 
European 1.2 
26,397 cases 
and 41,481 
controls 
OR per 
SD 
European 
Two-
sample 
Maximum 
likelihood 
1.17 (1.00-
1.36) 
0.049** 
Weighted median, mode-based estimates, MR-
Egger, leave-one-out analysis 
No Unknown 
Cornish AJ, 
201977 
Serum calcium 
1.000|OR≤0.75 
or OR≥1.33 
39,400 
participants 
European 2.6 
26,397 cases 
and 41,481 
controls 
OR per 
SD 
European 
Two-
sample 
Maximum 
likelihood 
0.93 (0.83-
1.05) 
0.264** 
Weighted median, mode-based estimates, MR-
Egger, leave-one-out analysis 
No Unknown 
Cornish AJ, 
201977 
Serum vitamin A 
(retinol) 
0.879|OR≤0.75 
or OR≥1.33 
5,006 
participants 
Finland, US 0.7 
26,397 cases 
and 41,481 
controls 
OR per 
SD 
European 
Two-
sample 
Maximum 
likelihood 
1.07 (0.78-
1.47) 
0.663** 
Weighted median, mode-based estimates, MR-
Egger, leave-one-out analysis 
No Unknown 
Cornish AJ, 
201977 
Serum vitamin 
B12 
1.000|OR≤0.75 
or OR≥1.33 
45,576 & 
37,341 
participants 
Iceland, 
Denmark 
4.7 
26,397 cases 
and 41,481 
controls 
OR per 
SD 
European 
Two-
sample 
Maximum 
likelihood 
1.21 (1.04-
1.42) 
0.016** 
Weighted median, mode-based estimates, MR-
Egger, leave-one-out analysis 
No 
Likely non-
causal 
Cornish AJ, 
201977 
Serum vitamin B6 
0.994|OR≤0.75 
or OR≥1.33 
2,930 
participants 
/ 1.4 
26,397 cases 
and 41,481 
controls 
OR per 
SD 
European 
Two-
sample 
Wald ratio 
1.04 (0.90-
1.20) 
0.592** 
Weighted median, mode-based estimates, MR-
Egger, leave-one-out analysis 
No Unknown 
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Cornish AJ, 
201977 
Serum vitamin E 
0.857|OR≤0.75 
or OR≥1.33 
5,006 
participants 
European 0.7 
26,397 cases 
and 41,481 
controls 
OR per 
SD 
European 
Two-
sample 
Maximum 
likelihood 
0.94 (0.76-
1.17) 
0.600** 
Weighted median, mode-based estimates, MR-
Egger, leave-one-out analysis 
No Unknown 
Fatty acid/Lipid metabolism biomarkers 
May-Wilson S, 
201778 
Plasma Arachidic 
acid (20:0) (GRS) 
Limited power 
(not specified) 
38,000 parti
cipants 
European / 
9,254 cases 
and 18,386 
controls 
OR per 
SD 
European 
Two-
sample 
Meta-analysis of 
statistics for each 
specific fatty acid 
generated for 
each CRC cohort 
was combined 
under fixed-
effects models 
0.92(0.61,1.39) 0.700 
Where more than one instrument variant was 
available: heterogeneity assessment, random-
effects inverse-variance weighted MR; assessing 
impact of pleiotropy by using IVW and MR-Egger 
methods 
No Unknown 
May-Wilson S, 
201778 
Plasma Palmitic 
acid (16:0) (GRS) 
Limited power 
(not specified) 
38,000 parti
cipants 
European 0.21-0.98 
9,254 cases 
and 18,386 
controls 
OR per 
SD 
European 
Two-
sample 
Meta-analysis of 
statistics for each 
specific fatty acid 
generated for 
each CRC cohort 
was combined 
under fixed-
effects models 
0.97(0.78,1.21) 0.820 
Where more than one instrument variant was 
available: heterogeneity assessment, random-
effects inverse-variance weighted MR; assessing 
impact of pleiotropy by using IVW and MR-Egger 
methods 
No Unknown 
May-Wilson S, 
201778 
Plasma Stearic 
acid (18:0) (GRS) 
Limited power 
(not specified) 
38,000 parti
cipants 
European 
0.01-1.39 
per SNP 
9,254 cases 
and 18,386 
controls 
OR per 
SD 
European 
Two-
sample 
Meta-analysis of 
statistics for each 
specific fatty acid 
generated for 
each CRC cohort 
was combined 
under fixed-
effects models 
1.16(1.01,1.35) 0.040 
Where more than one instrument variant was 
available: heterogeneity assessment, random-
effects inverse-variance weighted MR; assessing 
impact of pleiotropy by using IVW and MR-Egger 
methods 
No Unknown 
May-Wilson S, 
201778 
Plasma DHA 
(22:6n-3) (GRS) 
Limited power 
(not specified) 
38,000 parti
cipants 
European 0.7 
9,254 cases 
and 18,386 
controls 
OR per 
SD 
European 
Two-
sample 
Meta-analysis of 
statistics for each 
specific fatty acid 
generated for 
each CRC cohort 
was combined 
under fixed-
effects models 
1.32(0.94,1.87) 0.110 
Where more than one instrument variant was 
available: heterogeneity assessment, random-
effects IVW MR; assessing impact of pleiotropy 
by using IVW and MR-Egger methods 
No Unknown 
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Liyanage UE, 
201979 
Plasma DHA 
22:6n-3 
/ 
8,866 partici
pants 
European 0.65 
4,545 cases 
and 270,342 
controls 
combined 
9,254 cases 
and 18,386 
controls 
OR per 
SD 
European 
Two-
sample 
Wald-type ratio 
estimator 
(combining 
estimate with 
those from May-
Wilson et al 2017) 
1.07(0.84,1.36) 0.583* 
IVW estimate without combining with data from 
other study (May-Wilson et al 2017) 
No Unknown 
May-Wilson S, 
201778 
Plasma DPA 
(22:5n-3) (GRS) 
Limited power 
(not specified) 
38,000 parti
cipants 
European 
2.8-8.6 
per SNP 
9,254 cases 
and 18,386 
controls 
OR per 
SD 
European 
Two-
sample 
Meta-analysis of 
statistics for each 
specific fatty acid 
generated for 
each CRC cohort 
was combined 
under fixed-
effects models 
1.58(0.99,2.52) 0.060 
Where more than one instrument variant was 
available: heterogeneity assessment, random-
effects inverse-variance weighted MR; assessing 
impact of pleiotropy by using IVW and MR-Egger 
methods 
No Unknown 
Liyanage UE, 
201979 
Plasma EPA 
20:5n-3 
/ 
8,866 partici
pants 
European 2.05 
4,545 cases 
and 270,342 
controls 
combined 
9,254 cases 
and 18,386 
controls 
OR per 
SD 
European 
Two-
sample 
IVW (combining 
estimate with 
those from May-
Wilson et al 2017) 
1.06(0.91,1.22) 0.455* 
IVW estimate without combining with data from 
other study (May-Wilson et al 2017) 
No Unknown 
May-Wilson S, 
201778 
Plasma EPA 
(20:5n-3) (GRS) 
<0.1 
38,000 parti
cipants 
European 0.4 
9,254 cases 
and 18,386 
controls 
OR per 
SD 
European 
Two-
sample 
Meta-analysis of 
statistics for each 
specific fatty acid 
generated for 
each CRC cohort 
was combined 
under fixed-
effects models 
0.39(0.13,1.21) 0.100 
Where more than one instrument variant was 
available: heterogeneity assessment, random-
effects inverse-variance weighted MR; assessing 
impact of pleiotropy by using IVW and MR-Egger 
methods 
No Unknown 
Liyanage UE, 
201979 
Plasma DPA 
20:5n-3 
/ 
8,866 partici
pants 
European 11.12 
4,545 cases 
and 270,342 
controls 
combined 
9,254 cases 
and 18,386 
controls 
OR per 
SD 
European 
Two-
sample 
IVW (combining 
estimate with 
those from May-
Wilson et al 2017) 
1.10(1.01,1.19) 0.034* 
IVW estimate without combining with data from 
other study (May-Wilson et al 2017) 
No Unknown 
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May-Wilson S, 
201778 
Plasma AA (20:4n-
6) (GRS) 
Limited power 
(not specified) 
38,000 parti
cipants 
European 
0.1-37.6 
per SNP 
9,254 cases 
and 18,386 
controls 
OR per 
SD 
European 
Two-
sample 
Meta-analysis of 
statistics for each 
specific fatty acid 
generated for 
each CRC cohort 
was combined 
under fixed-
effects models 
1.05(1.02,1.07) 1.70E-04 
Where more than one instrument variant was 
available: heterogeneity assessment, random-
effects inverse-variance weighted MR; assessing 
impact of pleiotropy by using IVW and MR-Egger 
methods 
Yes 
Evidence of 
causality 
Liyanage UE, 
201979 
Plasma AA 20:4n-
6 
/ 
8,631 
participants 
White 
adults 
33.07 
4,545 cases 
and 270,342 
controls 
combined 
9,254 cases 
and 18,386 
controls 
OR per 
SD 
European 
Two-
sample 
IVW (combining 
estimate with 
those from May-
Wilson et al 2017) 
1.05(1.03,1.07) 
2.00E-
05* 
IVW estimate without combining with data from 
other study (May-Wilson et al 2017) 
No Unknown 
May-Wilson S, 
201778 
Plasma DGLA 
(20:3n-6) (GRS) 
Limited power 
(not specified) 
38,000 parti
cipants 
European 
2-11.1 
per SNP 
9,254 cases 
and 18,386 
controls 
OR per 
SD 
European 
Two-
sample 
Meta-analysis of 
statistics for each 
specific fatty acid 
generated for 
each CRC cohort 
was combined 
under fixed-
effects models 
0.91(0.83,1.00) 0.060 
Where more than one instrument variant was 
available: heterogeneity assessment, random-
effects inverse-variance weighted MR; assessing 
impact of pleiotropy by using IVW and MR-Egger 
methods 
No Unknown 
May-Wilson S, 
201778 
Plasma LA (18:2n-
6) (GRS) 
Limited power 
(not specified) 
38,000 parti
cipants 
European 
0.2-18.1 
per SNP 
9,254 cases 
and 18,386 
controls 
OR per 
SD 
European 
Two-
sample 
Meta-analysis of 
statistics for each 
specific fatty acid 
generated for 
each CRC cohort 
was combined 
under fixed-
effects models 
0.95(0.93,0.98) 3.70E-04 
Where more than one instrument variant was 
available: heterogeneity assessment, random-
effects IVW MR; assessing impact of pleiotropy 
by using IVW and MR-Egger methods 
Yes 
Evidence of 
causality 
Liyanage UE, 
201979 
Plasma LA 18:2n-
6 
/ 
8,631 
participants 
White 
adults 
8.3 
4,545 cases 
and 270,342 
controls 
combined 
9,254 cases 
OR per 
SD 
European 
Two-
sample 
IVW (combining 
estimate with 
those from May-
Wilson et al 2017) 
0.95(0.93,0.97) 
9.60E-
05* 
IVW estimate without combining with other 
study 
No Unknown 
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and 18,386 
controls 
May-Wilson S, 
201778 
Plasma Oleic acid 
(18:1n-9) (GRS) 
Limited power 
(not specified) 
38,000 parti
cipants 
European 
0.32-2.14 
per SNP 
9,254 cases 
and 18,386 
controls 
OR per 
SD 
European 
Two-
sample 
Meta-analysis of 
statistics for each 
specific fatty acid 
generated for 
each CRC cohort 
was combined 
under fixed-
effects models 
0.77(0.65,0.92) 0.004 
Where more than one instrument variant was 
available: heterogeneity assessment, random-
effects IVW MR; assessing impact of pleiotropy 
by using IVW and MR-Egger methods 
Yes 
Evidence of 
causality 
May-Wilson S, 
201778 
Plasma 
Palmitoleic acid 
(16:1n-7) (GRS) 
Limited power 
(not specified) 
38,000 parti
cipants 
European 
0.01-1.57 
per SNP 
9,254 cases 
and 18,386 
controls 
OR per 
SD 
European 
Two-
sample 
Meta-analysis of 
statistics for each 
specific fatty acid 
generated for 
each CRC cohort 
was combined 
under fixed-
effects models 
0.36(0.15,0.84) 0.018 
Where more than one instrument variant was 
available: heterogeneity assessment, random-
effects IVW MR; assessing impact of pleiotropy 
by using IVW and MR-Egger methods 
No Unknown 
Liyanage UE, 
201979 
Plasma ALA 
18:3n-3 
/ 
8,866 partici
pants 
European 1.03 
4,545 cases 
and 270,342 
controls 
combined 
9,254 cases 
and 18,386 
controls 
OR per 
SD 
European 
Two-
sample 
Wald-type ratio 
estimator 
(combining 
estimate with 
those from May-
Wilson et al 2017) 
0.89(0.78,1.02) 0.098* 
IVW estimate without combining with other 
study 
No Unknown 
Rodriguez-
Broadbent H, 
201780 
Total cholesterol 
(GRS) 
/ 
188,577 
participants 
European 
8-11 per 
SNP 
9,254 cases 
and 18,386 
controls 
OR per 
SD 
European 
Two-
sample 
IVW 1.46(1.20,1.79) 1.68E-04 
Restricted allele score based on SNPs exclusively 
associated with total cholesterol; LD regression; 
MR-Egger; omission two strongest SNPs 
Yes 
Evidence of 
causality 
Rodriguez-
Broadbent H, 
201780 
Triglyceride (GRS) 0.13 
188,577 
participants 
European 
8-11 per 
SNP 
9,254 cases 
and 18,386 
controls 
OR per 
SD 
European 
Two-
sample 
IVW 0.98(0.85,1.12) 0.752 
Restricted allele score based on SNPs exclusively 
associated with triglyceride; LD regression; MR-
Egger 
No Unknown 
Orho-Melander 
M, 201881 
Triglyceride (GRS) 0.8|OR≥1.77 
96,598 
participants 
European 4.9 
497 cases, 
26,904 
participants 
OR per 
SD 
Swedish 
Two-
sample 
Logistic 
regression 
1.16(0.78,1.74) / 
Multivariable MR analysis adjusting for the three 
lipid traits. 
No Unknown 
Rodriguez-
Broadbent H, 
201780 
LDL (GRS) 0.68 
188,577 
participants 
European 
8-11 per 
SNP 
9,254 cases 
and 18,386 
controls 
OR per 
SD 
European 
Two-
sample 
IVW 1.05(0.92,1.18) 0.485 
Restricted allele score based on SNPs exclusively 
associated with LDL; LD regression; MR-Egger 
No Unknown 
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Orho-Melander 
M, 201881 
LDL (GRS) 0.8|OR≥1.61 
95,454 
participants 
European 7.1 
497 cases, 
26,904 
participants 
OR per 
SD 
Swedish 
Two-
sample 
Logistic 
regression 
1.18(0.85,1.65) / 
Multivariable MR analysis adjusting for the three 
lipid traits. 
No Unknown 
Orho-Melander 
M, 201881 
HDL (GRS) 0.8|OR≥1.68 
99,900 
participants 
European 6 
497 cases, 
26,904 
participants 
OR per 
SD 
Swedish 
Two-
sample 
Logistic 
regression 
0.92(0.65,1.33) / 
Multivariable MR analysis adjusting for the three 
lipid traits. 
No Unknown 
Rodriguez-
Broadbent H, 
201780 
HDL (GRS) 0.31 
188,577 
participants 
European 
8-11 per 
SNP 
9,254 cases 
and 18,386 
controls 
OR per 
SD 
European 
Two-
sample 
IVW 0.94(0.84,1.05) 0.273 
Restricted allele score based on SNPs exclusively 
associated with HDL; LD regression; MR-Egger 
No Unknown 
Cornish AJ, 
201977 
HDL 
1.000|OR≤0.75 
or OR≥1.33 
188,577 
participants 
European 6.1 
26,397 cases 
and 41,481 
controls 
OR per 
SD 
European 
Two-
sample 
Maximum 
likelihood 
1.03 (0.92-
1.14) 
0.620** 
Weighted median, mode-based estimates, MR-
Egger, leave-one-out analysis 
No Unknown 
Cornish AJ, 
201977 
LDL 
1.000|OR≤0.75 
or OR≥1.33 
188,577 
participants 
European 7.9 
26,397 cases 
and 41,481 
controls 
OR per 
SD 
European 
Two-
sample 
Maximum 
likelihood 
1.14 (1.04-
1.25) 
0.006** 
Weighted median, mode-based estimates, MR-
Egger, leave-one-out analysis 
No 
Likely non-
causal 
Cornish AJ, 
201977 
Mono-
unsaturated fatty 
acids 
0.493|OR≤0.75 
or OR≥1.33 
24,925 
participants 
European 0.3 
26,397 cases 
and 41,481 
controls 
OR per 
SD 
European 
Two-
sample 
Wald ratio 
1.07 (0.78-
1.46) 
0.672** 
Weighted median, mode-based estimates, MR-
Egger, leave-one-out analysis 
No Unknown 
Cornish AJ, 
201977 
Omega-6 
polyunsaturated 
fatty acids 
1.000|OR≤0.75 
or OR≥1.33 
24,925 
participants 
European 2.4 
26,397 cases 
and 41,481 
controls 
OR per 
SD 
European 
Two-
sample 
Maximum 
likelihood 
1.15 (0.98-
1.36) 
0.095** 
Weighted median, mode-based estimates, MR-
Egger, leave-one-out analysis 
No 
Likely non-
causal 
Cornish AJ, 
201977 
Total cholesterol 
1.000|OR≤0.75 
or OR≥1.33 
24,925 
participants 
European 9.5 
26,397 cases 
and 41,481 
controls 
OR per 
SD 
European 
Two-
sample 
Maximum 
likelihood 
1.09 (1.01-
1.18) 
0.025** 
Weighted median, mode-based estimates, MR-
Egger, leave-one-out analysis 
No 
Likely non-
causal 
Cornish AJ, 
201977 
Total triglycerides 
1.000|OR≤0.75 
or OR≥1.33 
188,577 
participants 
European 6.1 
26,397 cases 
and 41,481 
controls 
OR per 
SD 
European 
Two-
sample 
Maximum 
likelihood 
0.93 (0.84-
1.04) 
0.192** 
Weighted median, mode-based estimates, MR-
Egger, leave-one-out analysis 
No Unknown 
Inflammatory Markers 
Nimptsch K, 
201582 
C-reactive protein 
(Unweighted GRS) 
/ 
727 
participants 
European 2 to 3 
727 cases and 
727 controls 
OR per 
2-fold 
higher 
European 
One-
sample 
Conditional 
logistic regression 
1.74(1.06,2.85) / 
Investigation for sex-specific associations; 
adjustments for observationally measured 
smoking, education, alcohol consumption, 
dietary intake and physical activity influenced 
the risk estimates; probit regression models, 
analysis of individual single-nucleotide 
polymorphisms; using weighted GRS or 
Haplotype frequency as instrumental variable 
No Unknown 
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Wang X, 201883 
C-reactive protein 
(19 SNPs) 
0.825|OR≥1.12 
66,185 & 
40,473 
participants 
European 5 
30,480 cases 
and 22,844 
controls 
OR per 
SD 
European 
Two-
sample 
IVW 1.04(0.97,1.12) 0.256 
Subgroup analyses stratified by cancer sites and 
stages, sex, BMI, smoking, NSAID use, aspirin 
use, history of endoscopy, family history of CRC; 
Egger regression 
No Unknown 
Cornish AJ, 
201977 
Circulating C-
reactive protein 
1.000|OR≤0.75 
or OR≥1.33 
66,185 
participants 
European 3.6 
26,397 cases 
and 41,481 
controls 
OR per 
SD 
European 
Two-
sample 
Maximum 
likelihood 
0.95 (0.83-
1.10) 
0.527** 
Weighted median, mode-based estimates, MR-
Egger, leave-one-out analysis 
No Unknown 
Cornish AJ, 
201977 
Plasma IL-6 
receptor subunit 
alpha 
1.000|OR≤0.75 
or OR≥1.33 
3,301 
participants 
European 60.4 
26,397 cases 
and 41,481 
controls 
OR per 
SD 
European 
Two-
sample 
Wald ratio 
0.98 (0.96-
1.00) 
0.035** 
Weighted median, mode-based estimates, MR-
Egger, leave-one-out analysis 
No Unknown 
Insulin related markers 
Cornish AJ, 
201977 
Fasting glucose 
1.000|OR≤0.75 
or OR≥1.33 
96,496 
participants 
European 3.6 
26,397 cases 
and 41,481 
controls 
OR per 
SD 
European 
Two-
sample 
Maximum 
likelihood 
1.04 (0.92-
1.18) 
0.519** 
Weighted median, mode-based estimates, MR-
Egger, leave-one-out analysis 
No Unknown 
Cornish AJ, 
201977 
Fasting proinsulin 
1.000|OR≤0.75 
or OR≥1.33 
46,186 
participants 
European 6.1 
26,397 cases 
and 41,481 
controls 
OR per 
SD 
European 
Two-
sample 
Maximum 
likelihood 
0.97 (0.90-
1.03) 
0.310** 
Weighted median, mode-based estimates, MR-
Egger, leave-one-out analysis 
No Unknown 
Cornish AJ, 
201977 
HbA1C levels 
0.999|OR≤0.75 
or OR≥1.33 
46,368 
participants 
European 1.8 
26,397 cases 
and 41,481 
controls 
OR per 
SD 
European 
Two-
sample 
Maximum 
likelihood 
1.02 (0.85-
1.22) 
0.866** 
Weighted median, mode-based estimates, MR-
Egger, leave-one-out analysis 
No Unknown 
Cornish AJ, 
201977 
Plasma IGF−I 
0.995|OR≤0.75 
or OR≥1.33 
3301 
participants 
European 1.4 
26,397 cases 
and 41,481 
controls 
OR per 
SD 
European 
Two-
sample 
Wald ratio 
0.88 (0.76-
1.01) 
0.064** 
Weighted median, mode-based estimates, MR-
Egger, leave-one-out analysis 
No Unknown 
Other Biomarkers 
Zhang C, 201584 
Telomere length 
(GRS) 
0.8|OR≥1.22 
37,684 
&9,190 & 
2,240 
participants 
European 
0.06-0.2 
per SNP 
5,100 cases 
and 4,831 
controls 
OR per 
1000 
base 
pair 
increa
se 
European 
Two-
sample 
IVW 1.25(0.92,1.69) 0.150 
Stratified by age and sex; likelihood-based 
Mendelian randomization method; Alternative 
instrument selection strategy 
No 
Likely non-
causal 
Haycock PC, 
201785 
Telomere length 1 
9,190 
participants 
European / 
14,537 cases 
and 16,922 
controls 
OR per 
SD 
European 
Two-
sample 
Maximum 
likelihood 
1.09(0.91,1.31) 0.340 
Heterogeneity analysis, weighted median and 
MR-Egger 
No 
Likely non-
causal 
Protein& amino acid 
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Au Yeung SL, 
201986 
GDF-15 
0.8|OR≥1.11 
(R2=0.15) or 
OR≥1.10 
(R2=0.21) 
5,440 
participants 
European 15 or 21 
4,562 cases 
and 382,756 
controls 
OR per 
SD 
European 
Two-
sample 
IVW (Fixed effect) 0.91(0.80,1.04) / 
Multiplicative random effect IVW; Lead SNP 
analysis; MR-Egger intercept test; Mendelian 
randomisation restricted to instruments from 
the same gene region (PGPEP1 or GDF15)  
No Unknown 
Nimptsch K, 
201787 
Adiponectin 
(ADIPOQ allele 
score) 
0.8|OR≤0.61 
2,880 
participants 
European 
and US 
3 
1,253 cases 
and 1,627 
controls 
OR per 
score 
unit 
European 
and US 
One-
sample 
Conditional 
logistic regression 
0.97(0.91,1.04) 0.430 
Restriction to Caucasians; Effect estimate in 
different study (HPFS and NHS); summary 
instrumental variable analysis using published 
data on genetic associations with adiponectin 
and colorectal cancer in a likelihood-based 
approach 
No Unknown 
Nimptsch K, 
201787 
Adiponectin 
(Incorporating the 
ADIPOQ allele 
score and plasma 
adiponectin 
concentrations) 
0.8|OR≤0.76 
2,880 
participants 
European 
and US 
/ 
1,253 cases 
and 1,627 
controls 
OR per 
score 
unit 
European 
and US 
One-
sample 
Conditional 
logistic regression 
0.73(0.40,1.34) / 
Restriction to Caucasians; Effect estimate in 
different study (HPFS and NHS) 
No 
Likely non-
causal 
Nimptsch K, 
201588 
Fetuin-A (AHSG 
allele-score) 
Limited power 
(not specified) 
1,367 cases 
and 1,367 
controls 
Western 
European 
21 
1,367 cases 
and 1,367 
controls 
RR per 
40mg/
ml 
higher 
(aappr
ox 1 
SD) 
Western 
European 
One-
sample 
Logistic 
regression 
0.98(0.73,1.33) / 
Conditional logistic regression models 
additionally adjusted for matching factors and 
BMI 
No Unknown 
Cornish AJ, 
201977 
Blood carnitine 
1.000|OR≤0.75 
or OR≥1.33 
7,824 
participants 
European 13.9 
26,397 cases 
and 41,481 
controls 
OR per 
SD 
European 
Two-
sample 
Maximum 
likelihood 
0.99 (0.92-
1.06) 
0.682** 
Weighted median, mode-based estimates, MR-
Egger, leave-one-out analysis 
No Unknown 
Cornish AJ, 
201977 
Blood methionine 
0.676|OR≤0.75 
or OR≥1.33 
7,824 
participants 
European 0.4 
26,397 cases 
and 41,481 
controls 
OR per 
SD 
European 
Two-
sample 
Wald ratio 
0.92 (0.70-
1.19) 
0.505** 
Weighted median, mode-based estimates, MR-
Egger, leave-one-out analysis 
No Unknown 
Cornish AJ, 
201977 
Circulating 
adiponectin 
1.000|OR≤0.75 
or OR≥1.33 
39,883 
participants 
European 1.8 
26,397 cases 
and 41,481 
controls 
OR per 
SD 
European 
Two-
sample 
Maximum 
likelihood 
0.93 (0.81-
1.07) 
0.309** 
Weighted median, mode-based estimates, MR-
Egger, leave-one-out analysis 
No Unknown 
Cornish AJ, 
201977 
Circulating fetuin-
A 
1.000|OR≤0.75 
or OR≥1.33 
9,055 & 
2,119 
participants 
European, 
African 
American 
14.3 
26,397 cases 
and 41,481 
controls 
OR per 
SD 
European 
Two-
sample 
Wald ratio 
0.98 (0.94-
1.02) 
0.370** 
Weighted median, mode-based estimates, MR-
Egger, leave-one-out analysis 
No Unknown 
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Cornish AJ, 
201977 
Serum 
immunoglobulin E 
0.997|OR≤0.75 
or OR≥1.33 
6,819 
participants 
European 1.6 
26,397 cases 
and 41,481 
controls 
OR per 
SD 
European 
Two-
sample 
Maximum 
likelihood 
0.92 (0.82-
1.03) 
0.159** 
Weighted median, mode-based estimates, MR-
Egger, leave-one-out analysis 
No Unknown 
*: statistically significant threshold set up at P≤0.0001; **: statistically significant threshold set up at P≤0.0013, GI: genetic instrument, SNP: Single Nucleotide Polymorphism, OR: odds ratio, HR: hazard ratio, SD: standard deviation, GRS: genetic risk score, BMI: body mass index, IVW: inverse variance weighted, EPA: 
Eicosapentaenoic acid, DHA: Docosahexaenoic acid, DPA: Docosapentaenoic acid, AA: arachidonic acid, DGLA: dihomo-γ-linolenic acid, LA: linoleic acid, ALA: α-Linolenic acid, HDL: high-density lipoprotein cholesterol, LD: linkage disequilibrium, LDL: low-density lipoprotein cholesterol, IL-6: interleukin 6, HbA1C: glycated 
hemoglobin, IGF-1: insulin-like growth factor 1, GDF-15: Growth differentiation factor 15. 
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Supplementary Table 6 Summary of overlapped meta-analyses of observational studies and 
Mendelian randomization studies 
Overlapped results from meta-analyses of observational studies 
Biomarker No. of overlapping 
studies 
Agreement of Direction 
of Point Estimate 
Agreement of Presence of 
Nominal Significance (p<0.05) 
Reference 
H. pylori infection 9 Y N 6-12,20 
HPV 8 Y Y 13-19 
Vitamin B9 [Folate] 6 N N 35-38 
Vitamin B12 5 N N 36,38,39 
Vitamin B6 5 Y Y 36,41,42 
Vitamin B2 2 Y N 36,40 
25-hydroxyvitamin D 10 Y Y 45-51 
CRP 3 Y Y 23-25 
IL-6 2 Y NON 24,26 
Fasting Glucose 6 Y Y 27,28,30,31 
C peptide 3 Y Y 27-29 
IGF 1 3 Y Y 32,33 
IGF 2 2 Y Y 32,34 
IGFBP 3 2 Y NON 32,89 
Triglycerides 3 Y N 2,3 
HDL–cholesterol 2 Y Y 2,3 
Adiponectin 7 N N 59-63,90 
Leptin 4 Y N 62,66,90 
Homocysteine 3 Y Y 36,38 
Telomere Length 3 Y N 57,58 
Overlapped results from Mendelian randomisation studies 
25-hydroxyvitamin D  8 N NON 72-77 
Adiponectin 3 Y NON 77,87,91 
Fetuin-A 2 Y NON 77,88 
DHA 22:6n-3 2 Y NON 78,79 
DPA 20:5n-3 2 Y NON 78,79 
EPA 20:5n-3 2 N NON 78,79 
AA 20:4n-6 2 Y Y 78,79 
LA 18:2n-6 2 Y Y 78,79 
Triglyceride 3 N NON 77,80,81 
LDL–cholesterol 3 Y NON 80,81 
HDL–cholesterol 3 N NON 80,81 
Total cholesterol 2 Y N 77,80 
C-reactive protein 3 N N 82,83 
Telomere length 2 Y NON 84,85 
Comparison between the largest meta-analyses of observational studies and the largest Mendelian randomisation studies 
25-hydroxyvitamin D  / Y N 49,72 
Selenium / Y NON 44,77 
Vitamin B12 / N N 36,77 
Vitamin B6 / N N 41,77 
Vitamin E / Y NON 53,77 
Zinc / N NON 54,77 
DHA 22:6n-3 / N N 1,78 
EPA 20:5n-3 / N N 1,78 
DPA 20:5n-3 / N NON 1,78 
Total cholesterol / Y NON 3,80 
Triglyceride / N NON 3,80 
LDL–cholesterol / Y NON 3,80 
HDL–cholesterol / N NON 3,80 
C-reactive protein / Y N 24,83 
IL-6  / N NON 24,77 
Fasting glucose / Y N 27,77 
HbA1C / Y NON 27,77 
IGF−I  / N N 32,77 
Adiponectin / Y N 59,77 
Telomere length / Y NON 58,85 
Y: agree, N: disagree, NON: non-significant association has been identified, CRC: colorectal cancer, H. pylori: helicobacter pylori, HPV: human papillomavirus 
infection, CRP: C-reactive protein, IL-6: Interleukin 6, IGF 1/2: Insulin-like growth factor 1/2, IGFBP 3: Insulin-like growth factor-binding protein 3, HDL: high-
density lipoprotein cholesterol, LDL: low-density lipoprotein cholesterol, DHA: Docosahexaenoic acid, DPA: Docosapentaenoic acid, EPA: Eicosapentaenoic 
acid, AA: arachidonic acid, LA: linoleic acid, HbA1c: glycated hemoglobin 
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Supplementary Table 7 Characteristics and main findings of meta-analyses of observational studies reporting unique non-genetic biomarkers and CRC risk 
(DL, PM, HKSJ estimators) 
Author/Year Biomarker 
No of 
studies 
No of 
cases 
No of 
participants 
Metric 
Effect size, DL 
(95%CI) 
P, DL I2, DL 
PEgger, 
DL 
95%PI, DL 
Effect size, PM 
(95%CI) 
Fatty acid/Lipid metabolism biomarkers 
Yang B,2014 LC n-3 PUFA 3 421 1,826 RR 0.58(0.40,0.84) 0.0042 0.00% 0.78 0.58(0.40,0.84) 0.58(0.40,0.84) 
Yang B,2014 Biospecimen EPA 20:5 (n-3) 4 421 1,826 RR 0.64(0.43,0.94) 0.0242 0.00% 0.48  0.64(0.43,0.94) 0.64(0.43,0.94) 
Yang B,2014 Biospecimen DHA 22:6 (n-3) 4 421 1,826 RR 0.53(0.32,0.87) 0.0124 27.00% 0.12 0.53(0.32,0.87) 0.53(0.32,0.88) 
Yang B,2014 Biospecimen DPA 22:5 (n-3) 3 243 1,366 RR 0.57(0.33,0.98) 0.0433 15.54% 0.44 0.57(0.33,0.98) 0.57(0.32,0.99) 
Yang B,2014 Blood EPA 20:5 (n-3) 5 195 384 SMD -0.76(-1.55,0.03) 0.0603 93.24% 0.00 -0.76(-1.56,0.03) -0.99(-2.89,0.92) 
Yang B,2014 Blood DHA 22:6 (n-3) 5 195 384 SMD -0.09(-0.27,0.09) 0.3098 0.00% 0.31  -0.09(-0.27,0.09) -0.10(-0.27,0.09) 
Yang B,2014 Blood DPA 22:5 (n-3) 5 195 384 SMD 0.36(-0.10,0.83) 0.1245 81.83% 0.00 0.36(-0.10,0.83) 0.43(-0.27,1.12) 
Yang B,2014 Adipose EPA 20:5 (n-3) 2 93 204 SMD 0.07(-0.20,0.35) 0.6024 0.00% / 0.07(-0.20,0.35) 0.08(-0.20,0.35) 
Yang B,2014 Adipose DHA 22:6 (n-3) 2 93 204 SMD -0.02(-0.35,0.30) 0.892 26.74% / -0.02(-0.35,0.30) -0.02(-0.35,0.30) 
Yang B,2014 Adipose DPA 22:5 (n-3) 2 93 204 SMD 0.12(-0.16,0.39) 0.4081 0.00% / 0.12(-0.16,0.39) 0.12(-0.16,0.39) 
Yao X,2015 HDL 12 2,542 136,698 RR 0.84(0.69,1.02) 0.0768 42.55% 0.39  0.84(0.69,1.02) 0.84(0.69,1.02) 
Yao X,2015 LDL 5 1,626 9,175 RR 1.04(0.60,1.81) 0.8906 82.66% 0.13 1.04(0.60,1.81) 1.04(0.57,1.92) 
Yao X,2015 Total cholesterol 28 10,892 7,725,310 RR 1.11(1.01,1.21) 0.0294 46.75% 0.54  1.11(1.01,1.21) 1.11(0.99,1.24) 
Yao X,2015 Triglyceride 19 8,127 2,252,217 RR 1.18(1.04, 1.34) 0.012 47.77% 0.20 1.18(1.04,1.33) 1.17(1.02,1.35) 
Infectious agents 
Ibragimova MK,2018 HPV 17 1,722 2,468 RR 2.69(1.86,3.90) 1.61E-07 25.50% 0.10 2.70(1.86,3.90) 2.93(1.87,4.57) 
Bai B,2016 Human cytomegalovirus 
infection 
4 480 960 OR  6.47(4.40,9.52) 2.91E-21 0.00% 0.73 6.47(4.40,9.52) 6.47(4.40,9.52) 
Boleij A,2011 Streptococcus bovis 6 189 340 OR 9.68(4.99,18.81) 2.03E-11 0.00% 0.51 9.68(4.99,18.81) 9.68(4.99,18.81) 
Liu C,2016 H.pylori 20 3,228 4,377 OR 1.37(1.10,1.71) 0.0048 61.09% 0.78 1.37(1.10,1.71) 1.38(1.04,1.84)  
Repass J,2018 F. nucleatum  2 139 278 r 0.40(0.17,0.62) 0.0005 34.95% /  0.38(0.17,0.55) 0.40(0.17,0.62) 
Liu H,2016 Enterobacteriaceae 2 37 76 SMD 2.62(0.55,4.69) 0.0133 88.74% /  2.62(0.55,4.69)  2.62(0.55,4.69) 
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Liu H,2016 Bifidobacterium 4 127 315 SMD -3.24(-6.47, -0.02) 0.0486 98.25% 0.06 -3.24(-6.47, -0.02) -3.24(-6.33, -0.15) 
Liu H,2016 Faecalibacterium prausnitzii 3 86 233 SMD -0.32(-0.59, -0.05) 0.0192 0.00% 0.63 -0.32(-0.59, -0.05) -0.32(-0.59, -0.05) 
Liu H,2016 Total bacteria 3 86 233 SMD 0.21(-0.53,0.96) 0.5758 75.81% 0.05 0.21(-0.53,0.96) 0.29(-0.75,1.32) 
Krishnan S,2014 Streptococcus bovis in faeces 3 148 414 OR 2.84(0.48,16.74) 0.2483 66.82% 0.18 2.84(0.48,16.74) 3.10(0.68,14.20)  
Liu H,2016 Lactobacillus 4 127 315 SMD -1.78(-3.76, 0.20) 0.0787 97.31% 0.03 -1.78(-3.76,0.20) -1.85(-5.35,1.66) 
Liu H,2016 Bacteroides-Prevotella group 3 97 255 SMD -0.70(-2.53,1.14) 0.4552 96.27% 0.84 -0.70(-2.53,1.14) -0.70(-2.35,0.95) 
Liu H,2016 Escherichia coli 2 90 239 SMD 1.38(-1.36,4.12) 0.3239 98.00% /  1.38(-1.36,4.12) 1.38(-1.36,4.12) 
Inflammatory Markers 
Zhou B,2014 CRP 18 4,779 152,942 RR 1.12(1.05,1.21) 0.0013 51.74% 0.02 1.12(1.05,1.20) 1.13(1.04,1.23) 
Zhou B,2014  IL-6 6 1,125 9,909 RR 1.10(0.88,1.36) 0.4012 34.82% 0.11 1.10(0.88,1.36) 1.10(0.88,1.36) 
Insulin related biomarkers 
Xu J,2016 Fasting glucose  26 20,390 5,105,567 RR  1.23(1.11,1.36) 8.92E-05 40.90% 0.00 1.23(1.11,1.36) 1.23(1.11,1.36) 
Xu J,2016 HOMA-IR  9 2,956 18,358 RR 1.54(1.23,1.92) 0.0001 30.60% 0.12 1.54(1.23,1.92) 1.52(1.24,1.86) 
Xu J,2016 Fasting insulin  11 3,191 26,301 OR 1.15(1.19,1.69) 1.28E-04 0.00% 0.70 1.42(1.19,1.69) 1.42(1.19,1.69) 
Chi F,2013  IGF 1 17 3,807 11,613 OR 1.28(1.07,1.53) 0.0061 20.62% 0.17 1.28(1.07,1.53) 1.28(1.07,1.54) 
Chi F,2013  IGF 2 6 783 4,007 OR 1.52(1.09,2.11) 0.0134 14.94% 0.64 1.52(1.09,2.11) 1.52(1.08,2.12) 
Chi F,2013  IGFBP 1 7 2,154 6,439 OR 0.85(0.69,1.04) 0.1043 3.68% 0.26  0.85(0.69,1.04) 0.84(0.69,1.04) 
Chi F,2013  IGFBP 2 3 1,348 2,962 OR 0.77(0.41,1.43) 0.4006 68.21% 0.01 0.77(0.41,1.43) 0.77(0.41,1.43) 
Chi F,2013  IGFBP 3 16 3,755 11,509 OR 0.88(0.71,1.10)  0.2680 45.74% 0.31 0.88(0.71,1.10) 0.88(0.69,1.11)    
Xu J,2016 HbA1c 8 2,137 45,569 RR 1.23(0.98,1.54) 0.0719 24.77% 0.31  1.23(0.98,1.54) 1.23(0.97,1.55) 
Xu J,2016 C-peptide 11 3,211 13,888 RR 1.32(1.02,1.70) 0.0325 48.09% 0.50 1.32(1.02,1.70) 1.34(0.99,1.79) 
Micronutrients 
Ma YL,2011 25-hydroxyvitamin D  10 3,142 7,840 RR 0.68(0.57,0.81) 2.87E-05 0.00% 0.61 0.68(0.57,0.82) 0.68(0.57,0.81) 
Lee JE,2011 1,25-dihydroxyvitamin D 4 625 1,801 OR 1.02(0.66,1.56) 0.9357 39.13% 0.63 1.02(0.66,1.56)  1.01(0.67,1.53) 
Ben S, 2018 Vitamin B2  2 1,593 32,962 RR 0.73(0.59,0.92) 0.0069 0.00% / 0.74(0.59,0.92) 0.73(0.59,0.92) 
Larsson SC,2010 Vitamin B6 4 883 2,207 RR 0.52(0.38,0.71) 4.39E-05 0.00% 0.97 0.52(0.38,0.71) 0.52(0.38,0.71) 
S. Shiao SPK,2018 Vitamin B12   8 3,296 8,290 SMD -0.07(-0.13, -0.003) 0.0378 52.44% 0.00 -0.07(-0.19,0.05) -0.05(-0.12,-0.002) 
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Zhang D, 2015 Folate 12 1,159 2,982 SMD -1.01(-1.52, -0.51) 7.66E-05 98.01% 0.00 -1.01(-1.93, -0.10)  -1.29(-2.27, -0.31) 
Dong YH,2017 Vitamin E 9 310 5,927 SMD -0.74(-1.30, -0.17) 0.0108 92.33% 0.00  -0.74(-1.31, -0.17)  -0.79(-1.63,0.05) 
Vinceti M,2018 Selenium 8 2,627 712,746 OR 0.86(0.70,1.06) 0.1585 0.00% 0.84 0.86(0.70,1.06) 0.86(0.70,1.06) 
Gumulec J,2014 Serum Zinc  5 313 529 SMD 0.05(-2.55,2.64) 0.9725 98.98% 0.66 0.05(-2.55,2.64) 0.05(-3.47,3.56) 
Gumulec J,2014 Tissue Zinc 10 234 398 SMD -0.24(-1.50,1.02) 0.7088 95.34% 0.00 -0.24(-1.50,1.02)  -0.70(-2.84,1.45) 
Other Biomarkers 
Zhang BL,2015 Blood group O 8 6,931 3,219,151 OR 0.90(0.86,0.95) 5.78E-05 0.00% 0.22 0.90(0.86,0.95) 0.90(0.86,0.95) 
Zhang BL,2015 Blood group AB 8 6,931 3,191,289 OR  0.97(0.86,1.10) 0.6443 0.00% 0.41 0.97(0.86,1.10)  0.97(0.86,1.10) 
Zhang BL,2015 Blood group A 8 6,931 3,214,941 OR  1.03(0.96,1.12) 0.3794 43.35% 0.07 1.04(0.96,1.12) 1.02(0.92,1.13) 
Zhang BL,2015 Blood group B 8 6,931 3,193,532 OR 1.01(0.93,1.09)  0.8975 0.00% 0.40 1.01(0.93,1.09) 1.01(0.93,1.09) 
Naing C,2017 Telomere Length 8 951 2,569 OR 1.01(0.77,1.34) 0.9270 30.40% 0.24 1.01(0.77,1.34) 1.01(0.77,1.34) 
Jiang R,2016 Enterolactone  3 762 2,408 RR 1.11(0.93, 1.32) 0.2668 44.60% 0.06 1.11(0.93,1.32) 1.12(0.92,1.36) 
Protein& amino acids 
Lu S,2017 Total Adiponectin 8 3,420 8,937 RR 0.79(0.68,0.92) 0.0024 5.37% 0.35 0.79(0.68,0.92) 0.79(0.68,0.92) 
Yang G,2016 Resistin 11 965 2,290 SMD 0.65(0.24,1.05) 0.0016 93.12% 0.94 0.65(0.24,1.05) 0.65(0.19,1.10) 
Shiao SPK,2018 Homocysteine 8 4,047 9,604 SMD 0.13(0.03, 0.22) 0.0072 74.80% 0.73 0.13(-0.04,0.29) 0.12(0.05,0.20) 
Yu DH,2018  Angiogenin  2 188 240 SMD 1.53(0.49,2.58) 0.0043 88.33% /  1.53(0.48,2.58) 1.53(0.48,2.58) 
Xing XJ,2014 MMP7 10 625 1,020 SMD 2.15(1.46,2.84) 9.65E-10 94.65% 0.00  2.15(0.90,3.40) 2.31(0.90,3.72) 
Li XX,2014 TLR-4 protein 3 168 283 OR 4.75(1.16,19.37) 0.0300 77.43% 0.00  4.75(1.16,19.37) 4.76(1.14,19.83) 
Sun SJ,2016 HER‑2(human epidermal 
growth factor receptor 2) 
expression 
13 932 1,453 OR  10.43(5.48,19.89) 8.77E-11 63.02% 0.00 10.43(5.48,19.88)  11.33(5.44,23.59) 
Feng Z, 2015 Ferritin 7 277 927 SMD -1.56(-2.70, -0.41) 0.0079 97.47% 0.00 -1.56(-2.70, -0.41) -1.57(-3.06, -0.08) 
Ouyang Z,2017 CD26 9 952 1,809 SMD -0.33(-2.97,2.30) 0.8033 99.63% 0.27 -0.34(-5.11,4.44)   
Gialamas SP,2013 Leptin 23 3,508 7,478 SMD 0.18(-0.04,0.40) 0.1094 94.01% 0.41  0.18(-0.22,0.58) 0.20(-0.32,0.72) 
CRC: colorectal cancer, HKSJ: Hartung-Knapp-Sidik-Jonkman, 1PEgger: The P value for small study effect test, 2Psig: The P value for excess significance test, RR: risk ratio, SMD: standard mean difference, OR: odds 
ratio, r: standardized correlation coefficient, LC n-3 PUFA: long chain n-3 polyunsaturated fatty acid, EPA: Eicosapentaenoic acid, DHA: Docosahexaenoic acid, DPA: Docosapentaenoic acid, HDL: high-density 
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lipoprotein cholesterol, LDL: low-density lipoprotein cholesterol, HPV: Human papillomavirus, CRP: C-reactive protein, IL-6: Interleukin 6, HOMA-IR: homeostatic model assessment-insulin resistance, IGF 1/2: Insulin-
like growth factor 1/2, IGFBP 1/2/3: Insulin-like growth factor-binding protein 1/2/3, HbA1c: glycated hemoglobin, MMP7: matrix metalloproteinase-7, CD26: dipeptidyl peptidase IV. 
 
 
Supplementary Table 7 (Continued) 
Biomarker P, PM I2, PM PEgger, PM 95%PI, PM Effect size, HKSJ (95%CI)  P, HKSJ I2, HKSJ PEgger, HKSJ 95%PI, HKSJ 
Fatty acid/Lipid metabolism biomarkers 
LC n-3 PUFA 0.0042 0.00% 0.78 0.58(0.40,0.84) 0.58(0.40,0.84) 0.0042 0.21% 0.78 0.58(0.40,0.84) 
Biospecimen EPA 20:5 (n-3) 0.0242 0.00% 0.48 0.64(0.43,0.94) 0.64(0.42,0.96) 0.0314 9.24% 0.50 0.64(0.42,0.96) 
Biospecimen DHA 22:6 (n-3) 0.0142 30.68% 0.12 0.53(0.32,0.88) 0.51(0.28,0.93) 0.0266 46.59% 0.19 0.51(0.28,0.93) 
Biospecimen DPA 22:5 (n-3) 0.0458 17.69% 0.44 0.57(0.33,0.99) 0.56(0.29,1.07) 0.0788 37.89% 0.46 0.56(0.30,1.07) 
Blood EPA 20:5 (n-3) 0.3104 98.89% 0.01 -0.98(-2.89,0.92) -0.98(-2.87,0.91) 0.3080 98.87% 0.01 -0.98(-2.87,0.91) 
Blood DHA 22:6 (n-3) 0.3098 0.00% 0.31 -0.09(-0.27,0.09) -0.07(-0.31,0.17) 0.5718 35.10% 0.41 -0.07(-0.31,0.17) 
Blood DPA 22:5 (n-3) 0.2293 92.11% 0.00 0.43(-0.27,1.12) 0.43(-0.27,1.12) 0.2292 92.11% 0.00 0.43(-0.27,1.12) 
Adipose EPA 20:5 (n-3) 0.6024 0.00% / 0.07(-0.20,0.35) 0.07(-0.21,0.36) 0.6083 3.39% /  0.07(-0.21,0.36)  
Adipose DHA 22:6 (n-3) 0.8920 26.74% / -0.02(-0.35,0.30)  -0.02(-0.37,0.32)  0.8999 35.64% / -0.02(-0.37,0.32) 
Adipose DPA 22:5 (n-3) 0.4081 0.00% / 0.12(-0.16,0.39) 0.12(-0.16,0.39) 0.4082 0.07% / 0.12(-0.16,0.40) 
HDL 0.0727 40.66% 0.40 0.84(0.69,1.02) 0.83(0.67,1.04)  0.1043 53.08% 0.39 0.83(0.67,1.04) 
LDL 0.8909 85.73% 0.15 1.04(0.57,1.92) 1.04(0.57,1.92) 0.8908 85.67% 0.16 1.04(0.57,1.92) 
Total cholesterol 0.0688 66.89% 0.57 1.11(0.99,1.25) 1.11(0.98,1.27) 0.1043 76.10% 0.60 1.12(0.98,1.27) 
Triglyceride 0.0239 55.92% 0.20 1.17(1.02,1.35) 1.17(0.99,1.36) 0.0598 47.77% 0.22 1.17(0.99,1.37) 
Infectious agents 
HPV 2.41E-06 41.28% 0.15 2.93(1.87,4.57)  3.52(1.77,7.00) 0.0003 75.66% 0.6453 3.52(1.77,7.00) 
Human cytomegalovirus infection 2.91E-21 0.00% 0.73 6.47(4.40,9.52) 6.47(4.23,9.89) 6.78E-18 13.74% 0.70 6.47(4.23,9.89) 
Streptococcus bovis 2.03E-11 0.00% 0.51 9.68(4.99,18.81) 9.44(4.43,20.11) 5.95E-09 18.72% 0.57 9.44(4.43,20.11) 
H.pylori 0.0277 78.87% 0.88 1.38(1.04,1.84) 1.38(1.01,1.89) 4.00E-02 82.00% 0.90 1.38(1.02,1.89) 
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F. nucleatum  0.0005 34.95% /  0.38(0.17,0.55) 0.40(0.16,0.63) 0.0010 40.05% / 0.38(0.16,0.56) 
Enterobacteriaceae 0.0133 88.74% / 2.62(0.55,4.69) 2.62(0.62,4.61) 0.0101 87.87% / 2.62(0.62,4.61) 
Bifidobacterium 0.0397 98.09% 0.07 -3.24(-6.33, -0.15) -3.24(-6.32, -0.16) 0.0390 98.08% 0.07 -3.24(-6.32,-0.16) 
Faecalibacterium prausnitzii 0.0192 0.00% 0.63 -0.32(-0.59,-0.05) -0.31(-0.69,0.06) 0.1000 25.76% 0.60 -0.31(-0.69,0.06) 
Total bacteria 0.5842 87.64% 0.05 0.29(-0.75,1.32) 0.29(-0.74,1.31) 0.5825 87.31% 0.07  0.29(-0.74,1.31) 
Streptococcus bovis in faeces 0.1457 56.38% 0.18 3.10(0.68,14.20) 3.10(0.68,14.20) 0.1456 56.37% 0.23 3.10(0.68,14.20) 
Lactobacillus 0.3014 99.15% 0.19 -1.85(-5.35,1.66) -1.85(-5.33,1.64) 0.2993 99.15% 0.19 -1.85(-5.33,1.64) 
Bacteroides-Prevotella group 0.4072 95.38% 0.84 -0.70(-2.35,0.95) -0.70(-2.33,0.94) 0.4030 95.30% 0.83 -0.70(-2.33,0.94) 
Escherichia coli 0.3239 98.00% / 1.38(-1.36,4.12) 1.38(-1.34,4.10) 0.3195 97.96% /  1.38(-1.34,4.10) 
Inflammatory Markers 
CRP 0.0031 65.11% 0.03 1.13(1.04,1.23) 1.14(1.04,1.25) 0.0059 72.80% 0.05 1.14(1.04,1.25) 
 IL-6 0.4029 35.06% 0.11 1.10(0.88,1.36) 1.09(0.85,1.39) 0.4959 47.99% 0.19 1.09(0.85,1.39) 
Insulin related biomarkers 
Fasting glucose  9.60E-05 42.10% 0.00 1.23(1.11,1.36) 1.27(1.11,1.45) 0.0006 66.17% 0.0106 1.27(1.11,1.45) 
HOMA-IR  5.76E-05 20.89% 0.10 1.52(1.24,1.86) 1.56(1.22,1.98) 0.0003 38.91% 0.18  1.56(1.22,1.98) 
Fasting insulin  1.28E-04 0.00% 0.70 1.42(1.19,1.69) 1.40(1.12,1.74) 0.0031 24.65% 0.86 1.40(1.12,1.74)  
IGF 1 0.0069 23.68% 0.18  1.28(1.07,1.54) 1.31(1.05,1.63) 0.0187 48.42% 0.28 1.31(1.05,1.63) 
IGF 2 0.0153 16.80% 0.65 1.52(1.08,2.12) 1.52(0.99,2.34) 0.0549 42.30% 0.62 1.52(0.99,2.34)  
IGFBP 1 0.1056 4.90% 0.26 0.84(0.69,1.04) 0.81(0.61,1.08) 0.1585 43.13% 0.42 0.81(0.61,1.09) 
IGFBP 2 0.4008 68.29% 0.01 0.77(0.41,1.43) 0.76(0.41,1.43) 0.4016 68.77% 0.02 0.77(0.41,1.43) 
IGFBP 3 0.2844 51.93% 0.32 0.88(0.69,1.11) 0.88(0.70,1.10) 0.2680 45.74% 0.31 0.88 0.71 1.10 
HbA1c 0.0814 89.56% 0.31 1.23(0.97,1.56) 1.25(0.93,1.67) 0.1414 53.83% 0.30  1.25(0.93,1.67) 
C-peptide 0.0514 60.90% 0.63 1.34(0.99,1.79) 1.35(0.97,1.89) 0.0788 70.63% 0.73 1.35(0.97,1.89) 
Micronutrients 
25-hydroxyvitamin D  2.87E-05 0.00% 0.61 0.68(0.57,0.82) 0.67(0.54,0.83) 0.0002 20.49% 0.79 0.67(0.54,0.83) 
1,25-dihydroxyvitamin D 0.9443 34.36% 0.64 1.02(0.67,1.53) 1.02(0.66,1.59) 0.9302 42.59% 0.64  1.02(0.66,1.59) 
Vitamin B2  0.0069 0.00% / 0.74(0.59,0.92) 0.74(0.57,0.95) 0.0200 9.32% / 0.74(0.58,0.95) 
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Vitamin B6 4.75E-05 0.00% 0.97 0.52(0.38,0.71) 0.52(0.38,0.71) 0.0012 0.89% 0.97 0.52(0.38,0.72) 
Vitamin B12   0.0397 39.77% 0.00 -0.06(-0.16,0.04) -0.07(-0.14, -0.003) 0.0384 54.91% 0.03 -0.07(-0.19,0.05) 
Folate 0.0097 99.56% 0.04 -1.29(-3.06,0.48) -1.29(-2.29, -0.30) 0.0105 99.57% 0.04  -1.29(-3.09,0.51) 
Vitamin E 0.0650 96.62% 0.01 -0.79(-1.63,0.05) -0.79(-1.63,0.05) 0.0650 96.61% 0.01 -0.79(-1.63,0.05) 
Selenium 0.1585 0.00% 0.84 0.86(0.70,1.06) 0.86(0.62,1.18)  0.3509 42.92% 0.7895 0.86(0.62,1.18) 
Serum Zinc  0.9788 99.44% 0.73 0.05(-3.47,3.56) 0.05(-3.47,3.56) 0.9788 99.40% 0.73 0.05(-3.47,3.56)  
Tissue Zinc 0.5236 98.52% 0.00 -0.70(-2.84,1.45) -0.76(-3.08,1.55) 0.5187 98.75% 0.00 -0.76(-3.08,1.55) 
Other Biomarkers 
Blood group O 5.78E-05 0.00% 0.22 0.90(0.86,0.95) 0.91(0.84,0.99) 0.0445 54.58% 0.23 0.91(0.84,0.99) 
Blood group AB 0.6443 0.00% 0.41 0.97(0.86,1.10)  0.94(0.73,1.21) 0.6416 61.18% 0.44 0.94(0.73,1.21) 
Blood group A 0.6917 65.94% 0.08 1.02(0.92,1.13)  1.01(0.90,1.14)  0.8533 75.87% 0.12 1.01(0.90,1.14) 
Blood group B 0.8975 0.00% 0.40 1.01(0.93,1.09)  1.00(0.91,1.10) 0.9963 18.12% 0.41 1.00(0.91,1.10) 
Telomere Length 0.9272 30.34% 0.26  1.01(0.77,1.34)  1.02(0.75,1.40) 0.8842 42.82% 0.34 1.02(0.75,1.40) 
Enterolactone  0.2710 51.36% 0.06 1.12(0.92,1.36) 1.14(0.89,1.47) 0.2924 66.71% 0.06 1.14(0.89,1.47) 
Protein& amino acids 
Total Adiponectin 0.0025 6.14% 0.35 0.79(0.68,0.92) 0.78(0.65,0.95) 0.0143 39.81% 0.38 0.79(0.65,0.95) 
Resistin 0.0059 94.79% 0.94 0.65(0.19,1.11) 0.65(0.19,1.11) 0.0059 94.79% 0.94 0.65(0.19,1.11) 
Homocysteine 2.10E-03 65.62% 0.68 0.13(-0.02, 0.27) 0.13(0.04,0.21) 0.0030 68.35% 0.69 0.13(-0.03,0.28) 
 Angiogenin  0.0043 88.33% /  1.53(0.48,2.58) 1.53(0.52,2.54) 0.0030 87.41% / 1.53(0.52,2.54) 
MMP7 0.0013 98.80% 0.00 2.31(-0.24, 4.86) 2.31(0.91,3.71) 0.0013 98.80% 0.00 2.31(-0.24,4.86) 
TLR-4 protein 0.0320 78.07% 0.00 4.76(1.14, 19.83) 4.75(1.16,19.45) 0.0304 77.55% 0.01 4.75(1.16,19.46) 
HER‑2(human epidermal growth 
factor receptor 2) expression 
8.77E-11 71.76% 0.00 11.33(5.44,23.59) 11.82(5.36,26.08) 9.33E-10 63.02% 0.00 11.82(5.36,26.08) 
Ferritin 0.0391 98.51% 0.00 -1.57(-3.06, -0.08) -1.57(-3.06, -0.08) 0.0388 98.50% 0.00 -1.57(-3.06, -0.08) 
CD26 / / / / -0.33(-4.35,3.70) 0.8737 99.84% 0.45  -0.33(-7.62,6.97) 
Leptin 0.4544 99.03% 0.58 0.20(-0.75,1.14) 0.20(-0.32,0.72) 0.4551 99.03% 0.58 0.20(-0.75,1.14) 
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Supplementary Table 8 Meta-analyses of RCTs on supplementary micronutrients and CRC risk 
First author, 
year Ethicity Population 
Biomarker 
proxies Dose Comparison Duration 
No of 
studies 
No of 
event 
No of 
participants Metric  Model 
Effect size 
(95%CI) I2(%) 
Arain 
MA,201092 / 
Healthy people aged 
over 40 years old Vitamin E 
50mg/day; 
400IU/day; 
600IU/second day 
Placebo 7-10 years 4 574 94,069 RR Fixed  0.89(0.76,1.05) 7% 
Bjelakovic 
G,201493 / 
Healthy people or 
with low-trauma, 
osteoporotic or 
fractureisolated 
systolic hypertension 
aged over 50 years 
old 
Vitamin D3 
(Cholecalciferol) 
800IU/day; 800 IU 
plus calcium 1000 mg 
daily; 400 IU plus 
calcium 1000 mg 
daily; 1000IU/day 
plus calcium 1400 to 
1500 mg daily; 
100,000 IU/4 
months; 100,000 IU 
oral vitamin D/3-
monthly 
Placebo or 
no 
intervention 
1-7 
years 5 436 45,598 RR Random 1.11(0.92,1.34) 0% 
Bristow 
SM,201394 / 
Healthy people aged 
over 40 years old Calcium >500 mg/d Placebo 
2-5 
years 8 83 9,863 RR Random 1.38(0.89,2.15) 0% 
Druesne-
Pecollo 
N,201095 
/ Smokers or asbestos workers, or not 
Beta-carotene 
given singly or in 
combination 
with other 
antioxidants 
6–15 mg/day or 20–
30 mg/day Placebo 
4-25 
years 7 957 151,118 HR Fixed  0.96 (0.85,1.09) / 
Qin 
T,201596 Mixed 
Vascular disease, 
diabetes, colorectal 
adenoma patients or 
healthy people aged 
over 57 years old 
Folic acid 0.5-2.5mg/day Placebo 27-88 months 8 381 34,598 RR Fixed  1.00(0.82,1.22) 0% 
Qin 
X,201397 Mixed 
Vascular disease, 
diabetes, colorectal 
adenoma patients or 
healthy people aged 
over 57 years old 
Folic acid 0.5-2.5mg/day Placebo 36-88 months 7 377 33,824 RR Random 1.01(0.82,1.23) / 
RR: risk ratio; HR: hazard ratio 
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